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 ABSTRACT  
 
Object: The aim of this research was to explore the effects of single pretreatment dose of 
potential neuroprotective drugs in a focal cerebral ischemia-reperfusion (I-R) model. 
 
Methods: After the setting up and establisment of the selected animal model, forty-two 
Wistar male adult rats were subjected to right middle cerebral artery (MCA) intraluminal 
occlusion for 60 minutes, under continuously cortical perfusion monitoring. Rats were 
randomly divided into three groups: control (saline), recombinant human erythropoietin 
(rhEPO, 1.000 IU/kg)-treated and 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-
8, 5 mg/kg) -treated. Saline or drugs were administered 10 minutes before the onset of 
ischemia. At 24-hour reperfusion, animals were examined for neurological deficits, blood 
samples were collected and animals euthanized. The following parameters were blindly 
evaluated: brain infarct volume, ipsilateral hemispheric edema, neuron specific enolase (NSE) 
plasma levels, parenchyma histology, Fluoro-Jade positive neurons, p-Akt and total Akt 
expression, and p-Akt-positive nuclei. 
 
Results: Data demonstrated that for rhEPO-treated group severity of neurological deficits 
(p<0.001), brain edema (p<0.001), and NSE plasma levels (p<0.001) were significantly 
reduced when compared to control group. Infarct volume and counting number of 
degenerating neurons in the interest area were similar between these groups, however, 
perivascular edema was less marked following treatment. No variations on the expression or 
localization of p-Akt were seen. TDZD-8-treated group compared to control group had: 
reduced infarct volume (p<0.001) and hemispheric edema (p<0.001), diminished number of 
dying neurons (p<0.001), decreased serum rise of NSE (p<0.001), and improved neurological 
performance (p<0.001). Fewer signs of perivascular edema and increased p-Akt nucleus 
translocation (p<0.05) were found.  
 
Conclusions: Results suggest that TDZD-8 has neuroprotective effects due to a complex and 
mixed synergic interaction between direct neuronal GSK-3β inhibition and Akt modulation, 
but further research is required before this drug may become clinically available. 
Additionally, it is presented first evidence that prophylactic rhEPO administration at the 
considered dose, which has its safety profile well-described in humans, reduced brain edema 
xi
 and preserved the neuronal pool of the penumbra area following I-R-injury. These benefits 
appear to be the result of an indirect effect in brain swelling as a consequence of diminished 
blood-brain barrier disruption and not due to a direct rhEPO neuronal action in the infarct 
area. Erythropoietin is a potential therapy to prevent neuronal injury induced by intraoperative 
transient artery occlusion. A translational study is supported and a summary protocol for a 
putative clinical trial is proposed. 
 
 
Keywords: erythropoietin; intracranial aneurysm; ischemia reperfusion injury; 
neuroprotective agents; TDZD-8; transient clipping.  
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 RESUMO 
 
Objectivo: A interrupção transitória do fluxo sanguíneo de artérias cerebrais em doentes 
submetidos a cirurgia de aneurismas intracranianos é, por vezes, inevitável, podendo resultar 
em lesões de isquemia cerebral. O período de tempo de oclusão tolerado, sem repercussão 
neurológica, é difícil de prever e muito variável. Nestes doentes, o uso de fármacos 
neuroprotetores seria desejável. Esta investigação teve como objectivo avaliar compostos com 
potencial efeito cerebroprotetor, passíveis de serem utilizados profilaticamente em situações 
com necessidade de oclusão transitória de artérias cerebrais. Respeitando as recomendações 
para ensaios em animais e tendo em conta uma aproximação à realidade clínica, procedeu-se a 
um modelo animal de isquemia-reperfusão (I-R) cerebral focal. Na sequência de uma revisão 
da literatura, foram selecionados dois compostos: eritropoietina humana recombinante 
(rhEPO) e 4-benzil-2-metil-1,2,4-thiadiazolidina-3,5-diona (TDZD-8).  
A eritropoietina é uma hormona bem estudada, com propriedades anti-apoptóticas neuronais, 
de preservação da integridade da barreira hemato-encefálica (BHE), de promoção do aporte 
de oxigénio e de neurogénese após lesão cerebral. Em altas doses, o seu efeito neuroprotetor 
foi demonstrado em modelos de I-R cerebral focal.  
O TDZD-8, recentemente descrito, é um inibidor da cinase 3β da sintase do glicogénio (GSK-
3β) que atravessa a BHE com propriedades anti-inflamatórias e protetoras de órgãos e tecidos 
perante agressão.  Os ensaios clínicos aparentam um perfil de eficácia/segurança favorável e 
poderá ser aprovado a médio prazo para uso humano no tratamento da diabetes mellitus e de 
determinadas doenças neurológicas.  
 
Métodos: Após o desenvolvimento e a validação de um modelo de I-R cerebral focal no rato, 
foram avaliados de forma independente os efeitos de doses únicas de TDZD-8 e de rhEPO.  
Quarenta e dois ratos Wistar machos adultos foram submetidos a 60 minutos de isquemia da 
artéria cerebral media (ACM) direita sob monitorização contínua do fluxo sanguíneo cerebral 
com uma microsonda Doppler. Os animais foram distribuídos aleatoriamente por 3 grupos: 
grupo controlo (soro fisiológico), grupo tratamento TDZD-8 (5 mg/kg) e grupo tratamento 
rhEPO (1.000 UI/kg). As administrações dos compostos foram feitas por via endovenosa, 10 
minutos antes da indução da isquemia. Resumidamente, a técnica consistiu na introdução de 
um filamento de nylon 4-0 com a ponta revestida por silicone na artéria carótida externa, de 
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 forma retrógrada até à bifurcação da artéria carótida primitiva e posterior progressão pela 
artéria carótida interna até à sua bifurcação, ocluindo a ACM. A interrupção do fluxo 
sanguíneo na ACM era objetivada pela monitorização Doppler por uma queda abrupta para 
valores inferiores a 30% do valor basal. Após 60 minutos de isquemia, procedeu-se à remoção 
cuidadosa do filamento, restabelecendo-se a circulação na ACM. Às 24 horas de reperfusão, 
foi avaliada a condição neurológica e os animais submetidos a eutanásia para análise dos 
seguintes parâmetros: volume de infarto cerebral, edema hemisférico ipsilateral, níveis 
plasmáticos da enolase específica do neurónio (EEN), histologia do parênquima cerebral, 
quantificação dos neurónios positivos para Fluoro-Jade, expressão dos p-Akt e Akt total por 
Western Blot e quantificação dos núcleos positivos para p-Akt por imunohistoquímica. 
 
Resultados: Os resultados demonstraram que o grupo tratamento com rhEPO, quando 
comparado com o grupo controlo, apresentou uma redução significativa do grau de 
incapacidade neurológica (p<0.001), do edema cerebral (p<0.001) e dos níveis plasmáticos da 
EEN (p<0.001). Apesar de histologicamente se verificar uma menor acentuação do edema 
perivascular, o volume do infarto cerebral, a contagem de neurónios positivos para Fluoro-
Jade e a expressão e localização do p-Akt mostrou-se idêntica nos 2 grupos.  
O tratamento com TDZD-8 reduziu a extensão da lesão cerebral, o número de neurónios 
apoptóticos/degenerados (p<0.001), evitou a subida dos níveis plasmáticos da EEN (p<0.001) 
e melhorou significativamente a condição neurológica dos ratos às 24 horas de reperfusão 
(p<0.001). O grupo tratado com TDZD-8 apresentou reduções de 48% no volume do infarto 
cerebral (p<0.001) e de 59% no edema hemisférico (p<0.001) comparativamente com o grupo 
controlo. Ainda, no grupo tratado com TDZD-8, verificou-se menor acentuação de edema 
perivascular na área isquémica e embora os níveis de expressão de Akt total e p-Akt não 
tenham sofrido alterações significativas, verificou-se  translocação nuclear do p-Akt (p<0.05).  
 
Conclusões: A maioria dos estudos pré-clínicos referentes a fármacos neuroprotetores são 
desenhados para doentes com acidentes vasculares cerebrais em evolução. A subpopulação de 
doentes neurocirúrgicos submetidos a clipagem transitória de artérias cerebrais carece de 
investigação específica. Os resultados deste trabalho demonstram que a administração de 
TDZD-8 antes da indução de um período transitório de isquemia cerebral pode ter efeitos 
neuroprotetores que resultam de uma interação sinérgica entre a inibição da GSK-3β e a 
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 modulação da via Akt, pois apesar da expressão do p-Akt total não se ter alterado, a sua 
translocação nuclear sugere a ativação desta via. Efetivamente, esta via tem sido descrita e 
implicada como uma das principais promotoras da sobrevivência celular após lesão neuronal. 
O TDZD-8 é um composto muito investigado em vários campos da medicina sendo um 
fármaco promissor como protetor do sistema nervoso central. Para um completo 
esclarecimento dos seus mecanismos de ação na I-R, são necessários estudos complementares.  
Adicionalmente, demonstrou-se, no modelo animal, que a administração profilática de rhEPO 
numa dose única e com perfil de segurança bem conhecido no humano, 1.000 UI/kg, preserva 
o pool neuronal funcional da área de penumbra e diminui o edema cerebral associado à lesão 
induzida pela I-R. Surpreendentemente, ao contrário de estudos anteriores, a ausência da 
ativação da via Akt/GSK-3β sugere que os efeitos da administração de rhEPO não foram 
resultado de uma ação neuronal direta. Apenas uma pequena fracção da rhEPO administrada 
por via sistémica atravessa a BHE, pelo que a dose relativamente baixa de rhEPO utilizada 
neste estudo quando comparada com as doses utilizadas em ensaios anteriores, poderá ser a 
explicação. A preservação da integridade da BHE e a consequente diminuição do edema e 
lesão cerebral secundária parecem constituir o mecanismo base deste efeito protetor. 
Concluiu-se que a rhEPO, clinicamente disponível e acessível, é uma potencial terapêutica 
para prevenir lesão cerebral induzida pela oclusão intraoperatória transitória de artérias 
cerebrais. Os resultados deste trabalho suportam a realização de um estudo translacional, pelo 
que se propõe um protocolo resumido para um ensaio clínico.  
 
 
Palavras-chave: aneurisma intracraniano; clipagem transitória; eritropoietina; lesão de 
isquemia-reperfusão; fármacos neuroprotetores; TDZD-8. 
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 1   BACKGROUND 
 
 
1.1  Transient Focal Cerebral Ischemia for Cerebrovascular Procedures 
 
Intracranial aneurysms (IAs) are acquired dilatations of intracranial arteries that are typically 
located at bifurcation sites along the Circle of Willis, which are areas prone to hemodynamic 
patterns that potentiate aneurysm development1. Histologically, thinned and dilated regions of 
the vascular wall that exhibit loss of the internal elastic lamina, thinning of the tunica media, 
and subsequent remodeling and degradation of extracellular matrix proteins throughout the 
vessel wall is observed. IAs affect around 3% of the general adult population and represent a 
major public health problem, in which a fraction will rupture and lead to subarachnoid 
hemorrhage (SAH) with possible devastating consequences2. The incidence of SAH due to IA 
rupture, depending on geography, varies from 6-10 in most populations to up to 21 cases per 
100,000 person-years in Finland and Japan3-5. Typical symptoms include sudden onset of 
severe headache, nausea and, often, loss of consciousness. It is a serious neurosurgical 
emergency with poor prognosis; approximately 15% of patients die before admission and 
around 40% die in the hospital6. Only 25% of those who live past the first month recover 
completely, leaving many survivors requiring long-term care7. The key to minimizing the risk 
of rebleeding following aneurysmal rupture is to exclude the aneurysm from cerebral 
circulation. At present, this is achieved either by microsurgical clipping or endovascular 
coiling, although there has been much debate on the merits of each intervention. 
 
IAs were first described in autopsy reports by Morgagni in 17618. It was not until 1891, when 
Quinke introduced the lumbar puncture, that the diagnosis of SAH became possible in living 
patients9. The origin of both endovascular and surgical treatment of IAs goes back to 1927, 
when António Egas Moniz presented his newly developed technique of angiography in the 
Société de Neurologie de Paris10. This technique not only revolutionized the diagnostics of 
cerebral aneurysms but also had a key role in starting the development of IAs treatment. By 
1931 Egas Moniz was able to perform a complete angiogram and brain aneurysms could be 
diagnosed in living humans. In that same year, Norman Dott became the first surgeon to 
perform an elective intracranial surgery for the treatment of a diagnosed IA by means of 
angiography, wrapping it with muscle11. A few years later, in 1937, Walter Dandy was the 
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 first to treat an aneurysm by applying a silver clip (V-shaped) across the neck of an 
unruptured internal carotid artery aneurysm12. Modern era of IA surgery was launched in the 
sixties, when Lawrence Pool13 pioneered the use of the operating binocular microscope and 
Mahmut Gazi Yasargil introduced the fundamental microsurgical approaches and 
techniques14. Meanwhile, in 1964, Luessenhop who used inflatable balloons to occlude 
aneurysm and arteriovenous malformations gave initial steps towards interventional 
neuroradiology15. Later on, Serbinenko pioneered the use of detachable balloons16. The 
introduction of microcatheters and microguidewires by Target Therapeutics Inc. (Fremont, 
CA, USA) in 1986 was a big step in endovascular therapy, but endovascular techniques 
gained definite importance with the development of electrolytically detachable platinum coils 
by Guglielmi and Viñuela in the nineties17,18.  
 
Neurovascular procedures requiring transient focal cerebral ischemia are mostly related to 
IAs. The use of elective transient artery occlusion in IA surgery was first described by Pool in 
196119 and is now widely accepted amongst cerebrovascular surgeons. By reducing the 
pressure within the aneurysm, it became sometimes an essential approach for a safer 
dissection of the aneurysm neck, open of the aneurysm for thrombus removal, a definitive clip 
placement, and managing with an intraoperative rupture. Although a brief temporary 
interruption of arterial flow in virtually all intracranial vessels is safe, some circumstances 
may require more protracted time intervals of occlusion, which may threaten the viability of 
underperfused brain tissue. The period of stroke-free temporary occlusion varies considerably 
and depends on several clinical features, such as the degree, size, location and duration of the 
ischemia, presence and quantity of subarachnoid blood, timing of surgery, anatomical 
variability, reactivity of the circulation, patient’s age, body temperature, genetic factors and 
other co-morbidities such as atherosclerosis20-25. The risk of using temporary clips is not, 
however, only limited to the transient interruption of focal cerebral blood flow (CBF). Kühnel 
found that arteries are particularly sensitive to microvascular trauma due to temporary clips, 
in which maximal histological changes were seen in the tunica media, and that greater 
microvascular trauma was caused by increased occlusion force rather than by increased 
clipping time26. It is possible that these structural endothelial and smooth muscle changes 
promote the formation of microemboli and have a role in aggravating vasospasm after 
aneurysmatic SAH, leading to higher morbidity and mortality27. Even though commercially 
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 available temporary clips have lower occlusion force than definitive ones, specifically 
designed temporary clips with the minimum effective occlusion force would be desired28. 
This is a line of research that would deserve more investing. For instance, standard metal clips 
for temporary clipping may be cumbersome and difficult to place when the aneurysm 
ruptures. A different strategy for temporary arterial occlusion would be to position an 
unobtrusive remotely controlled occluding device in a parent artery and have it activated only 
if it turns out to be necessary. This would allow the surgeon to work under normal cerebral 
perfusion with the guarantee of a clean and immediate blood flow interruption if the situation 
arises. The use of remote-controlled occluders to limit transient vessel occlusion would be of 
interest as it could spare time spent on temporary clipping and thus, make aneurysm surgery 
safer.  
 
For obvious reasons, randomized prospective studies to compare the outcome of 
cerebrovascular procedures with temporary occlusion and those without local circulatory 
arrest are not feasible. Most reports on the use of temporary arterial occlusion in humans have 
been retrospective analyses of case series in which the use or nonuse of temporary occlusion 
was based on the experience and judgment of the surgeon. Samson29 reviewed 100 patients 
who underwent elective temporary arterial occlusion. Overall, 19% of patients demonstrated 
evidence of infarction in the vascular territories subjected to temporary arterial occlusion, 
with no registration of infarction attributed to temporary vessel occlusion of less than 14 
minutes. Increased age (more than 61 years) and higher Hunt and Hess grades (III to IV) were 
associated with limited tolerability of temporary vessel occlusion. The authors stressed that 
regarding specific vascular territories undergoing temporary occlusion, the basilar and middle 
cerebral arteries appeared to be the most sensitive to ischemia-reperfusion (I-R) injury. The 
incidence of postoperative radiographic evidence of infarction was lower for internal carotid, 
anterior cerebral, and vertebral artery occlusion. Ferch30 retrospectively analyzed 106 
aneurysm patients and found that an overall rate of 17% of patients experienced symptomatic 
stroke and 26% showed radiological evidence of brain infarct attributable to temporary 
arterial occlusion. Stroke incidence was 12% in patients subjected to occlusion time periods 
of less than 10 minutes and 35% in patients with ischemic periods higher than 10 minutes. A 
longer duration of clip placement, older patient age, a poor clinical grade (Hunt and Hess 
Grades IV-V), early surgery, and the use of single prolonged clip placement rather than 
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 repeated shorter episodes were associated with a higher risk of stroke.  
 
Temporary focal ischemia covers a complex cascade of events with a continuum of potential 
outcomes ranging from no measurable effect to devastating neurological injury. The duration 
of temporary occlusion remains the most investigated factor in clinical series of patients 
undergoing temporary artery occlusion. For sure, the safety time of temporary clipping is not 
the same for all patients with cerebral aneurysms, but it is generally recommended that the 
duration of temporary occlusion be limited to less than 5 to 14 minutes whenever possible to 
avoid ischemic damage and neurologic complications, although there are several reports of 
patients with longer periods of occlusion without signs of neurological deficits24,29,31-34. Still, 
while numbers vary, a significant proportion of patients, up to 45%, undergoing clipping 
surgery with transient vessel occlusion may suffer from brain infarct31. Conflicting opinions 
exist regarding the mode of transient occlusion. Although repeated clip applications may led 
to formation of new microthrombi or detachment of already existing wall vessel thrombi, 
usually, brief repetitive clipping periods are preferred rather than a single episode of 
protracted ischemia35-37.  
 
While neurosurgeons are regularly using temporary arterial occlusion for the management of 
both routine and complex IAs, reducing the risks as much as possible is critical to this 
procedure. More specifically, effective neuroprotective drugs for these patients are essential 
for a safer surgery. 
 
 
1.2 Cerebral Ischemia-Reperfusion Physiopathology 
 
The brain has high-energy demands requiring a continuous supply of oxygen and its principal 
substrate, glucose. Blood flow cessation to the brain leads to disruption of the balance 
between energy generated by oxidative phosphorylation and energy needed for cell processes. 
The most immediate biochemical change in neurons affected by ischemia is a switch from 
aerobic to anaerobic metabolism. Insufficient oxygen inhibits the aerobic catabolism of 
pyruvate and promotes anaerobic glycolysis, leading to an accumulation of lactic acid and the 
consequential decrease in pH values. Ischemia triggers a series of interrelated events 
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 culminating in cellular injury and death by affecting energy-dependent processes necessary 
for tissue cell survival (Figure 1.1). Each of the processes has a distinct time frame, some 
occurring over minutes, others over hours and days, causing injury to neurons, glia and 
endothelial cells.  
 
 
 
 
Figure 1.1. The cascade of biochemical events leading to cell death following 
cerebral ischemia and reperfusion. Reperfusion may also induce injury by 
enhancing BBB breakdown, inflammation and free radical production. AA, 
arachidonic acid; ATP, adenosine triphosphate; BBB, blood-brain barrier; CBF, 
cerebral blood flow; NO, nitric oxide; NOS, nitrous oxide synthase; PLA2, 
Phospholipase A2.  
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Cerebrovascular tissue undergoing ischemia has two layers: (a) inner core of the ischemic 
area, where blood flow is most severely restricted and necrosis of neuronal and supporting 
glial cells may occur within minutes; (b) periphery of the ischemic area (penumbra), supplied 
also by collaterals where blood flow can buffer the full effects of the stroke38. In the infarct 
core, where adenosine triphosphate (ATP) is severely depleted, necrosis may be the 
predominating form of cellular death, whereas in the penumbra, apoptosis, an energy-
dependent programmed form of cell death, may be the predominant form of cell death. The 
penumbra area is characterized by the loss of action potential firing but maintenance of proper 
resting membrane potential and represents a functionally impaired but potentially salvageable 
area. On restoration of blood flow to the penumbra territory, normal function may return. If 
flow is not restored acutely, tissue originally in the penumbral region dies and the core infarct 
region evolves to encompass what was previously penumbral tissue39.  
 
During ischemia, unless perfusion is improved in a timely fashion or cells are made relatively 
more resistant to injury, the tissue at risk dies within minutes to a few hours39. Even a partial 
occlusion for a long enough period may cause harmful effects due to deterioration of ion 
gradient and by-products of anaerobic metabolism40. Experimental evidence shows that 
reperfusion triggers a set of unique, potentially pathologic events including, for example, 
increased prostaglandin synthesis, elevated production of second messengers, inflammation, 
and mitochondrial dysfunction, as indicated by elevated reactive oxygen species (ROS) and 
the opening of the mitochondrial permeability transition pore41-43. The paradox of reperfusion 
injury can be understood in terms of counter-adaptive changes occurring during cerebral 
ischemia that predispose tissues to cellular dysfunction, apoptosis, and necrosis during the 
reperfusion phase. Reperfusion may enhance inflammatory response, oxidative stress and 
blood-brain barrier (BBB) disruption that could increase secondary brain injury, including 
cerebral edema and hemorrhagic transformation44.  
 
Rapid energy depletion reflects very low energy reserves within the brain, a high metabolic 
rate, and an almost total reliance on glucose oxidation for energy production. Ischemia 
depletes ATP within minutes, in which the immediate consequence is the perturbation of 
electrochemical membrane gradients, leading to depolarization. The pathophysiology of 
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 cerebral I-R is complex, and cell damage results from the interplay of ionic imbalance, 
excitotoxicity mechanisms, inflammatory pathways, oxidative stress, peri-infarct 
depolarizations (PIDs), apoptosis, and neuroprotection. 
 
Ionic imbalance 
The neuronal loss of calcium homeostasis is a hallmark of impending cell demise. 
Intracellular concentration of calcium is normally strictly regulated through control of ATP-
dependent calcium channels and exquisite active sequestering systems, including endoplasmic 
reticulum, lysosomes and mitochondria45. Ischemia causes an increase in calcium intracellular 
concentrations from depolarization of voltage-gated channels, activation of ligand-gated 
channels, release of intracytoplasmic stores, and loss of ATP-dependent calcium extrusion 
pathways, particularly the Na+/Ca2+ exchanger45,46. Excessive calcium influx results in the 
activation of a multitude of enzymes including phospholipases and proteases, mediated 
through calcium serving as a secondary messenger for numerous downstream signaling 
pathways47. Activation of phospholipases and proteases causes membrane and protein 
degradation, decreasing cellular integrity and survival if no ATP is available for the re-
synthesis of cellular constituents. Furthermore, endonucleases are also activated, potentiating 
cell death48. Calcium influx stimulates glutamate-mediated excitotoxicity as depolarization 
occurs and additional glutamate is released. In addition, activation of neuronal nitrous oxide 
synthase (NOS), phospholipase A2, and other Ca2+-dependent enzymes leads to production of 
nitric oxide (NO), arachidonic acid metabolites, and superoxide, which act as additional 
triggers of cell death47,49. Other channels and ion pumps activated during ischemia have also 
been implicated in the ionic imbalance such as acid-sensing ion channels (ASICs), volume-
regulated anion channels, and transient receptor potential channels50-53. The former, ASICs, 
are stimulated within the pH range commonly found in ischemic brain tissue, thus explaining 
the well-established link between acidosis, one of the hallmark neurochemical elements of the 
anaerobic metabolism of ischemia, and worsening of ischemic outcome in animals and 
humans. 
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Excitotoxicity mechanisms 
 
Glutamate is a major excitatory neurotransmitter in the mammalian brain and key mediator of 
communication, plasticity, growth and differentiation, The concentration of this 
neurotransmitter is usually maintained across the plasma membrane by sodium-dependent 
glutamate transporters located on pre- and postsynaptic membranes and, under normal 
homeostatic conditions, glutamate is rapidly cleared from the synapse via presynaptic and 
astrocyte uptake. During ischemia, membrane depolarization and intracellular accumulation 
of sodium lead to a reversal of glutamate transporters and allow glutamate to exit cells along 
its concentration gradient54. Also, breakdown of astrocytic functions results in impaired cell 
glutamate uptake55. The resulting glutamate concentration increase in the synapse results in 
prolonged and sustained stimulation of N-methyl-d-aspartate (NMDA) and α-amino-3-
hydroxy-5-methyl-4-propionate (AMPA) ionotropic receptors subtypes that further enhance 
the influx of calcium, sodium, water and, therefore, cytotoxic edema56.  
 
Peri-infarct depolarizations 
Besides excitotoxic events at the molecular and cellular level, the overwhelming release of 
glutamate and ionic imbalance negatively impact the evolution of ischemic injury at the tissue 
level. For instance, PIDs are spontaneous waves of electrochemical activity that propagate 
through the cortex following focal stroke. PIDs are triggered by high levels of extracellular 
glutamate and potassium and characterized by slowly propagating massive, high-energy 
consuming depolarization of neurons and astrocytes along with drastic disruption of ionic 
gradients57. Recurrent PIDs in the penumbra are associated with increased ischemic injury. 
The resulting infarct expansion is probably due to mismatch between high metabolic demand 
to support membrane repolarization and marginal tissue perfusion due to constrained 
penumbral blood flow. Electrophysiological and imaging data demonstrated cortical 
spreading depolarizations (CSD) in patients with ischemic stroke or with ruptured IAs and has 
been correlated with infarct maturation, vasospasm and delayed ischemic neurologic deficit 
following aneurysmal subarachnoid hemorrhage57-59. CSD has been shown to induce tone 
alterations in vessels, causing a physiological hemodynamic response of transient 
hyperperfusion in healthy tissue and an inverse hemodynamic response hypoperfusion in 
tissue at risk for progressive damage, which may enhance cortical spreading ischemia58. 
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Oxidative stress 
The brain is highly susceptible to free radical mediated insult due to its high lipid content and 
its limited antioxidant defenses60. Oxidative stress in cerebral I-R, induced by the production 
of ROS, can be attributed largely to mitochondrial dysfunction41-43. In I-R, excessive ROS 
results in a range of harmful events as endogenous scavenging systems may have been 
compromised by ischemia, therefore, inducing cell membrane disruption through 
phospholipid fatty acids peroxidation61. ROS block mitochondrial respiration by inhibiting 
enzymes involved in the electron transport chain and facilitate mitochondrial transition pore 
formation, which causes increased release of mitochondrial membrane constituents, in 
particularly apoptosis-related proteins62. Additionally, ROS may also cause damage to other 
fundamental cellular components such as nucleic acid or gene repair systems, leading to 
subsequent cell death by necrotic or apoptotic mode. It may activate various cell signaling 
pathways that are proposed to be involved in regulating cell survival/death, such as p38, c-Jun 
N-terminal kinases, p53, extracellular signal-regulated kinases 1/2, Akt (protein kinase B) 
pathway and the nuclear factor-κB (NF-κB)63. Nitric oxide is a vasodilator generated by 
endothelial NOS to increase local CBF during ischemia. The relatively low levels of NO 
produced by endothelial NOS are neuroprotective, whereas high levels of NO produced by 
macrophage NOS and induced NOS during ischemia may exacerbate or contribute to injury. 
High concentration of NO combines with superoxide to produce peroxynitrite, which is a 
potent oxidant64. Following reperfusion, as reoxygenation provides an excess supply of 
substrate for oxidation, there is even increased production of superoxide, NO and 
peroxynitrite64,65. These radicals activate matrix metalloproteases, which degrade collagen and 
laminins in the basal lamina resulting in disruption of the integrity of the vascular wall and 
increased BBB permeability66. ROS and reactive nitrogen species produced in mitochondria 
are involved in the release of cytochrome C and further pro-apoptotic proteins67. Oxidative 
and nitrative stress are simultaneously powerful mediators of ischemic injury and responsible 
for recruitment and migration of neutrophils and other leukocytes to the cerebral vasculature. 
Enzyme-release from these cells further increase basal lamina degradation and vascular 
permeability during reperfusion. These events can lead to parenchymal hemorrhage, 
vasogenic brain edema and neutrophil infiltration into the brain68. 
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 Inflammatory pathway/Apoptosis 
The inflammatory response to vascular occlusion is immediately initiated within the vessel 
and results in activation of complement, platelets, and endothelium69. Sequential expression 
of adhesion molecules, results first in neutrophil and later in monocyte adhesion to the 
endothelial wall. Within the vasculature, activated leukocytes contribute to vessel occlusion 
both directly and by releasing proinflammatory cytokines, proteases, and ROS, which injure 
the endothelial surface, leading to thrombus formation, vasospasm, and worsening ischemia69. 
Inflammatory mediators contribute to breakdown of the BBB, further promoting the 
infiltration of leukocytes into the brain. The choreographed inflammatory response progresses 
for many days after ischemia, with multiple signals and targets triggering expression of novel 
proteins and secondary infarct expansion. In neurons, cerebral ischemia upregulates the 
expression of several apoptosis, cytoskeletal, and proinflammatory genes, including 
transcription factors, heat shock proteins, cytokines, chemokines and adhesion molecules. The 
complex network of kinases involved in cell response to I-R includes glycogen synthase 
kinase-3β (GSK-3β), which plays a critical role in the promotion of apoptosis in neurons. 
GSK-3β kinase and its inhibition to suppress cell death will be a subject of discussion in a 
later chapter. Ischemic damage causes an early response in gene expression of p53 and release 
of proapoptotic molecules cytochrome c and apoptosis-inducing factor from mitochondria. 
This leads to activation of caspases and other genes that potentiate cell death70,71. NF-kB has 
also its expression increased during in vivo ischemia and has been demonstrated to have a key 
role in the regulation of genes involved at multiple stages of immune responses, 
inflammation, dendritic cell maturation and lymphocyte activation by modulating the 
expression of tumor necrosis factor-α, interleukin-1β, interleukin-6, inducible NOS, 
cycloxygenase-2 and intercellular adhesion molecule-160. In the periphery, NF-kB, was found 
to be expressed by activated macrophages, monocytes, lymphocytes, endothelial cells, 
fibroblasts, platelets, while in cerebral infarctions NF-kB has been seen to be induced in 
activated microglia and glial cells72. Similarly, numerous other metabolism-, cell 
communication- and signal transduction-related genes were found down-regulated at 6 hours 
after middle cerebral artery occlusion (MCAO)73. Remarkably, several phases of the 
neuroinflammatory response, including leukocyte infiltration, cytokine production and 
enzyme induction, significantly contribute to cause delayed I-R injury. 
 
10
 BBB disruption 
Cerebral edema resulting from stroke is an important cause of death and disability. Acute 
hypoxia causes cytotoxic edema within minutes to hours, potentially reversible, which gives 
way to vasogenic edema with progression of infarction. Cytotoxic/cellular edema is 
characterized by swelling of all cellular elements of the brain, including neurons, glia, and 
endothelial cells, due to an inflow of water as a result of failure of ATP-dependent sodium 
and calcium pump. Particularly, focal ischemia followed by reperfusion leads to severe 
damage to the BBB integrity, allowing water and macromolecules to cross into brain tissue as 
early as 20 to 45 minutes following MCAO74. This detrimental vasogenic edema may reduce 
focal blood flow becoming a vicious cycle, accelerating brain damage75. The sustained 
increase in the intracranial pressure can cause persistent ischemia, irreversible brain damage, 
and ultimately, cerebral herniation and death.  
 
Neuroprotection mechanisms 
Ischemic cascade also activates various neuroprotective mechanisms against apoptotic and 
necrotic cell death. These include heat shock protein 70, pro-survival Bcl-2 pathway, 
phosphorylated-Akt (p-Akt), neurotrophin-3, interleukin-10 or granulocyte-colony stimulating 
factor76-80. Furthermore there is an unclear importance of autophagy in I-R, which is an 
energy-dependent process used by eukaryotes to degrade and recycle subcellular organelles. 
Autophagy has been implicated in the death process81 but its role in ischemia may be 
cytoprotective, as demonstrated by some disease models82. As detailed, ischemia is mediated 
by highly redundant cellular, molecular, and physiological mechanisms involving neurons, 
astrocytes, and vascular cells. Upstream sensors have been implicated, including adenosine 
and its receptor, NMDA receptor, and the transcriptional regulator hypoxia inducible factor 
(HIF). HIF regulates a constellation of protective genes, including those whose protein 
products facilitate oxygen transport (erythropoietin), regulate glycolytic metabolism, and 
promote angiogenesis. The unexpected demonstration that a genetic deletion of HIF1α 
improves infarct volume after MCAO83 leads, however, to the finding that a complex network 
of transcriptional activations of HIF target genes pathogenic mechanisms may be dependent 
on the degree of hypoxia84. During mild hypoxia, the transcriptional activations of HIF-
inducible genes mainly promote cell survival by erythropoiesis, angiogenesis and anti-
apoptosis. During severe hypoxia, HIF effects are represented by its participation in the 
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 apoptotic process by increasing stability of tumor suppressor protein p53 and by inducing cell 
necrosis. 
 
 
1.3 Intraoperative Cerebral Protection 
Neuroprotection involves mechanisms and strategies to protect against neuronal injury or 
degeneration following acute disorders, such as stroke or trauma, or as a result of chronic 
neurodegenerative diseases. Specifically for cerebral hypoxia, it could be defined as any 
strategy, or combination of strategies, that antagonizes, interrupts, or delays the sequence of 
injurious biochemical and molecular events that, if left unchecked, would result in irreversible 
cerebral ischemic injury85. According to this classic definition, protection from injury is 
settled at the neuron itself and therefore, excludes therapeutic strategies that are directed 
primarily at the cerebral vasculature. The fact that all cell types participate in the complex 
pathophysiology of brain injury during ischemia, however, leads to the basis of the 
neurovascular unit model, providing a conceptual framework to integrate responses to an 
injury from all cell types, including neuronal, glial, and vascular cells86,87. Cell-to-cell 
interactions in the neurovascular unit form the basis for brain function. It is now clear that it is 
insufficient to approach brain function and dysfunction from a uniquely neuronal standpoint 
but whereas the intricate molecular pathways of cell death in the neuron have been dissected 
in detail, the mechanisms of how the entire neurovascular unit responds to I-R are not so 
clear. Moreover, how each cell type in the neurovascular unit might alter its response to 
ischemia in the context of different environments remains to be elucidated. The concept of 
neuroprotection, therefore, is shifting to the concept of cerebroprotection, in which the 
neurovascular unit takes advantage of the neuron86. The growing understanding that neuron 
protection solely and prevention of its death alone may not be enough, suggests that future 
therapeutic approaches should target multiple cell types in an attempt to protect their 
structural, functional integrity and reciprocal interactions. 
 
Prevention of iatrogenic brain ischemia in the operating room during cerebrovascular 
procedures includes non-pharmacological and pharmacological strategies. Precluding or 
limiting the duration of a transient artery occlusion is the most direct and obvious strategy. As 
the duration of stroke-free period for temporary artery occlusion, as earlier stated, is highly 
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 variable, intraoperative prediction of this time period for each particular patient is currently an 
important line of clinical research. The reports of use of electrophysiological monitoring such 
as electroencephalography, electrocorticography, multimodality and somatosensory evoked 
potentials monitoring to alter the course of the intraoperative management of IAs to minimize 
postoperative infarction are increasing25,88-91. Monitoring brain tissue oxygenation is also 
being investigated as a risk indicator of cerebral ischemia and post-operative infarction for 
aneurysm surgery92,93. Evidently, accomplishing vessel patency after aneurysmal clip 
placement is of higher importance, which is done with a meticulous surgical technique and 
could be confirmed with systems such as microvascular Doppler, fluorescent angiography 
with indocyanine green, ultrasonic flow probe or intraoperative angiography. 
 
Nonpharmacological strategies may also include maintenance of CBF by adequate control of 
mean arterial pressure, normoglycemia, and adequate hemoglobin levels. Also, whenever a 
transient occlusion of a cerebral artery is considered necessary, induction of hypertension may 
increase collateral perfusion of the ischemic penumbra and hence, increase cerebral tolerance 
to transient ischemia94. While avoiding hyperthermia is critical and consensual, inducing 
hypothermia is controversial and has been matter of intense research. Hypothermia has shown 
significant efficacy in animal models of cerebral ischemia95 and to be clinically feasible in 
surgical and acute stroke patients96-98. Still, hypothermia has failed to achieve effective 
neuroprotective effects in the clinical setting. The rationale of hypothermia was to protect the 
brain through a pleiotropic of effects within the neurovascular unit. It has been shown to 
reduce brain metabolism, glutamate release, ROS production, peri-infarct depolarizations, 
inflammatory markers, microglial activation, leukocyte infiltration, and BBB disruption99. 
Moreover, studies have shown that hypothermia suppresses apoptotic cell death, decreases 
mitochondrial release of cytochrome C and apoptosis-inducing factor and upregulates cell 
survival pathways99. Therefore, reducing the body core temperature illustrates, at least 
theoretically, the potential power of approaching stroke therapy using combinations of 
modalities that engage multiple cell types to enhance protection and recovery. However, 
several complications have been associated with hypothermia, including shivering, 
pneumonia, infections, hypotension, cardiac arrhythmias and an increase in intracranial 
pressure during the rewarming period. Kimme98 evaluated the safety of intraoperative 
moderate hypothermia in 326 patients who underwent 359 aneurysm-clipping operations. No 
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 significant difference in circulatory instability, coagulopathy, and infection was evident in 
comparison to previous studies. Pulmonary complications (ventilator dependency) were 
thought to be secondary to neurogenic pulmonary edema and could be ameliorated by rapid 
rewarming and early extubation. Efficacy outcomes were not evaluated. Other clinical trials 
were performed, namely the Intraoperative Hypothermia Aneursym Surgery Trial (IHAST)100, 
Cooling for Acute Ischaemic Brain Damage (COOL-AID) studies, COOL-AID I (using 
surface cooling)101, COOL-AID II (using endovascular cooling)96 and the Intravenous 
thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L)97. All 
showed that mild therapeutic hypothermia for acute ischemic stroke or in the intraoperative 
setting is feasible but had no change in clinical outcome. Lately, enthusiasm regarding the use 
of intraoperative hypothermia has fallen out of favor as a neuroprotective adjunct102-104, 
highlighting the need for the use of and research on cerebroprotective agents. Nevertheless, 
several other efficacy and safety clinical trials are ongoing: Cooling in Acute Stroke 
(COAST-II) trial, Controlled Hypothermia in Large Infarction (CHILI) trial, the European 
Stroke Research Network for Hypothermia (EuroHYP)-1 trial (protocols available at 
http://www.strokecenter.org), and The Intravascular Cooling in the Treatment of Stroke 
(ICTuS) trial105.  
 
The classic theory of pharmacological cerebral protection is based on the concept that by 
decreasing cerebral metabolic demand, the neuronal survival will improve during periods of 
inadequate CBF. Because barbiturates decrease cerebral metabolism, it was the first drug 
group to be considered as a potential cerebral protectant. It was demonstrated that barbiturates 
decreased cerebral metabolic activity in a dose-dependent manner, which produced 
progressive decrease in electroencephalogram (EEG) activity, reduction in the rate of ATP 
depletion, and protection from incomplete cerebral ischemia106. Therefore, with barbiturate 
treatment to an isoelectric EEG during ischemia, all metabolic energy is believed to be used 
for maintenance of basal cellular integrity. Accordingly, Nussmeier107 confirmed that 
barbiturates only work during incomplete ischemia, that is when EEG activity is still present 
during the ischemic period, and that barbiturates decrease cerebral metabolism in a dose-
dependent manner only until the EEG becomes isoelectric. One could expect similar effects in 
other anesthetics, such as etomidate, propofol or isoflurane, as they suppress 
neurotransmission. Lavine33 has probably reported the best clinical evidence so far regarding 
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 this issue, from a small retrospective analysis of 49 patients who underwent surgery for 
middle cerebral artery (MCA) aneurysms with transient vessel clipping. Thirty-eight patients 
received intravenous pentobarbital, etomidate, or propofol, whereas the remaining 11 inhaled 
isoflurane. Postoperative radiographic evidence of infarction was noted in 45% of patients 
receiving the inhaled agent as opposed to 16% of those who underwent intravenous 
anesthesia, suggesting a protective effect with their use during temporary intracranial vessel 
occlusion. Nevertheless, a secondary analysis of the large IHAS trial, which included 441 
patients who underwent temporary clipping during cerebral aneurysm surgery, concluded that 
supplemental pharmacologic agents such as barbiturates did not improve 24-hour or 3-month 
neurologic outcomes102. 
 
Up to date, there is no strong evidence that any of the commonly used drugs for patients 
undergoing transient cerebral clipping have effective cerebroprotective properties. 
 
 
1.4 Translation from bench to bedside 
 
Within the past few years, a wide variety of pharmacologic agents have shown beneficial 
effects in reducing infarct volume in animal stroke models. Therapies evaluated have included 
calcium channel blockers, glutamate antagonists, γ-aminobutyric acid (GABA) agonists, NOS 
inhibitors/free radical scavengers, phospholipid precursor, NO signal-transduction down-
regulator, leukocyte inhibitors, statins, hemodilution, and miscellaneous other agents. 
Translating these successes to the clinical sphere, however, has been complicated by 
inconsistent results and toxic side effects. In fact, over 1000 potential neuroprotective drugs 
have been tested in preclinical animal studies, in which around 100 progressed to clinical 
trials but, so far, none have proven efficacious for the human population108.  
 
The failed translation from bench to bedside of numerous drugs, however, has provided some 
important concerns for investigators to consider before designing a preclinical or considering 
a translational trial for a potential neuroprotective agent109-111: 
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 (1) Robust supportive preclinical data – Preclinical data should include sample size 
calculation, inclusion/exclusion criteria, randomization, allocation concealment, blinded 
assessment of outcome, adequate acute and long-term outcome measures 
(histopathological and functional response), disclosure of relevant conflicts of interest, 
and data should be sent for publishing for review in a peer-reviewed journal; 
(2) Definition of the route of administration and effective dose– Route of administration 
in preclinical trials should be feasible in real life. Also, there should be a target 
concentration, a tissue level of effect identified from animal studies, or a surrogate 
marker that, when the drug is given to humans, will give some indication of whether 
there is a reasonable prospect of achieving neuroprotection in human clinical trials. The 
translation of preclinically protective doses for clinical trials is frequently not possible to 
approximate because of dose-limiting toxicity in humans; 
(3) Consider time-window to treatment – In animal models, the time of the stroke or 
ischemic onset is known precisely, whereas in humans this may not be the case. Clinical 
trials should not evaluate a time-window to treatment significantly longer than was 
justified by the preclinical findings;  
(4) Approach as possible preclinical condition to clinical setting – An important reason 
for the failure of clinical trials to confirm positive results in animal studies may relate to 
the lack of direct linkage between the model and the clinical situation. For instance, if 
the mechanism of drug action suggests that reperfusion will be necessary for drug 
effect, clinical research should be linked to reperfusion as well. 
By far, most preclinical and clinical studies aiming toward neuroprotection were designed for 
patients with ongoing stroke, in which the treatment drug was administered after the onset of 
ischemia, as clinical setting would demand. Neurosurgical patients, although fewer in number, 
have the advantage of having several of the important variables controlled in the operating 
room, including the physiological parameters and the timing of the administration of 
cerebroprotective drug(s), which could even be done at or before the onset of the induced 
cerebral ischemia. It is intuitive that these circumstances may better resemble preclinical 
conditions of cerebral I-R produced in the laboratory and raise chances of clinical success. 
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 2   OBJECTIVES 
 
Main objectives of this research were: 
 
1. To set up and establish an intraluminal MCA I-R rat model suitable to investigate 
potential benefits of drugs as possible treatments against neuronal damage in surgical 
procedures that require transient cerebral artery occlusion; 
 
2. To investigate the potential benefits of a single dose of 1.000 IU/kg intravenous (IV) 
recombinant human erythropoietin (rhEPO) in the implemented I-R animal model; 
additionally, if results support it, to elaborate a protocol to promote a translational 
clinical trial; 
 3. To investigate the potential benefits of a single dose of 5 mg/kg IV 4-­‐benzyl-­‐2-­‐methyl-­‐1,2,4-­‐thiadiazolidine-­‐3,5-­‐dione (TDZD-8) in the implemented I-R animal 
model.	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 3   CEREBRAL ISCHEMIA-REPERFUSION ANIMAL MODEL 
 
3.1 Background 
 
Experimental animal models of cerebral ischemia, with or without reperfusion, are designed 
to allow investigators to recreate specific aspects of human brain ischemia to study 
pathophysiologic and neuroprotective mechanisms, as well as therapeutic responses under 
controlled conditions that cannot be done easily or at all in clinical patients. 
 
Rodents are particularly useful for stroke research because their cerebrovascular anatomy and 
physiology closely resemble that of humans and are reasonably inexpensive compared to 
larger animals112. The small brain volume of the rat is well suited for different analytical 
procedures and there are several well-described and standardized functional outcomes for rats 
in experimental stroke, including behavioral, cognitive, and sensorimotor outcomes113-117. 
Measurement of the extent of cerebral infarction is easily accomplished by histological 
staining for tissue damage using 2,3,5-triphenyltetrazolium chloride (TTC), cresyl violet 
(Nissl stain) or hematoxylin and eosin (H&E).  
 
Rodent models of cerebral ischemia can be classified as global or focal and as reversible or 
irreversible. Focal cerebral ischemia models are designed to induce ischemia by occlusion or 
blockage of major cerebral arteries, most commonly MCA. Middle cerebral artery occlusion 
can be proximal or distal, permanent or temporary, alone or combined with carotid artery 
occlusions (ipsi-, contra-, or bilateral). Occlusion methods include ligation with 
suture/clipping/electric cauterization, blood clot injection, photochemical thrombosis, 
stereotactic injection of endothelin-1, or intraluminal filament118-122.  
 
The Stroke Therapy Academic Industry Roundtable (STAIR)109,110 provided 
recommendations with the goal of improving preclinical stroke therapy assessment and 
increasing the translational potential of experimental stroke treatments. The whole design of 
this research intended to follow these guidelines, in which preclinical studies should closely 
replicate the clinical environment to increase the likelihood of translational success. 
Accordingly, a reversible focal cerebral ischemia model using an intraluminal filament was 
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 chosen, as this model is the one that best mimics the ischemia-reperfusion injury that occurs 
during intraoperative transient cerebral artery occlusion. Although this surgical model is 
demanding and has a learning curve, it does not require craniectomy or brain manipulation, 
and the resulting proximal MCAO produces a big infarction that involves both cortical and 
subcortical areas.  
 
In this chapter, a description of the technique implemented in the Pharmacology & 
Translational Research Laboratory of the Faculdade de Farmácia da Universidade de Lisboa 
is done, followed by preliminary results that allowed establishment of the MCA I-R rat 
model. Assessments of drug experiments are described in subsequent chapters. 
 
Animal care was followed in accordance with the recommendations of the European 
Convention for the Protection of Vertebrate Animals Used for Experimental and Other 
Scientific Purposes (Council Directive 2010/63/UE) and National Law 113/2013 (rules for 
protection of experimental animals). The Ethics Committee of Faculdade de Medicina da 
Universidade de Lisboa approved all animal procedures. All efforts were made to minimize 
animal suffering and to reduce the number of animals used. 
 
 
3.2 Materials and Methods 
 
 
3.2.1 Middle Cerebral Artery Ischemia-Reperfusion Technique 
Adult Wistar male rats weighting between 280 to 350 g housed under diurnal light conditions 
with unlimited access to food and water were used.  
 
Male animals were used on the assumption that pathophysiology and treatment outcome does 
not differ amongst gender and to reduce experimental variability caused by female hormone 
cycling. Rats were food deprived for a period of 12 hours prior to surgery.  
 
The MCA I-R surgical procedure performed is essentially a noninvasive method of reversible 
MCAO by the use of an intraluminal suture, originally described by Koizumi120, with some 
minor modifications (Figure 3.1).  
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Figure 3.1. Diagram of the cranial circulatory system of the rat showing a silicone-
coated intraluminal suture in place occluding the origin of the MCA. The OA and STA 
branches off of the left ECA have been ligated and a suture tie around the ECA stump 
holds the intraluminal thread in place. ACA, anterior communicating artery; CCA, 
common carotid artery; ECA, external carotid artery; ICA, internal carotid artery; OA, 
occipital artery; PComA, posterior communicating artery; PPA, pterygopalatine artery; 
STA, superior thyroid artery.  
 
During the course of the experiments, general anesthesia was induced. Intraperitoneal (IP) 
pentobarbital administration (60 mg/kg) was used during experimental setting, and 
supplemented as required. Later, with the use of experimental drugs, ketamine (80 mg/kg) and 
xylazine (8 mg/kg) IP mixture was used to avoid potential neuroprotective effects of 
pentobarbital. Below, a step-by-step description for the surgical procedure is provided: 
 
1. The anesthetized animal is placed on a pre-warmed thermoregulatory heating pad and 
a temperature probe is inserted about 2 to 3 cm into the rectum. Body temperature is 
displayed on the control unit’s temperature monitor and maintained between 36.5ºC to 
37,5ºC. 
2. Artificial tear ointment is applied to both eyes to protect the corneas from drying. 
3. The animal is positioned in ventral position and the skin and fur on the head is 
disinfected with 70% alcohol solution. 
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 4. A midline head incision is done to expose the bregma, retractors put in place and a 
small burr hole is drilled 2 mm posterior to the bregma and 3.5 mm lateral to the 
midline down to dura-mater in the supply territory of the right MCA, where transient 
ischemia is to be done. A micro-Doppler holder probe is glued with cyanoacrylate to 
the bone and the Laser-Doppler probe put in place (Periflux System 4000, Probe 407, 
Perimed-Instruments, Stockholm, Sweden) (Figure 3.2, A-D). The skin incision is 
closed with a 2-0 silk suture. 
5. The animal is then changed to supine position with a pad under the neck to slightly 
extend it to aid vessel exposure (Figure 3.2, E).  
6. Skin and fur on the ventral cervical area is disinfected with 70% alcohol solution. 
7. Under the operating microscope, a ventral midline neck incision is made and the 
superficial fascia dissected; the right sides of the sternohyoid muscle, which lies 
midline over the trachea, sternomastoid muscle laterally and digastric muscle 
superiorly, are blunt dissected and gently retracted to expose the right common carotid 
artery (CCA). The omohyoid muscle is retracted downwards with a silk line and 
retractors are positioned between the sternomastoid and sternohyoid muscles (Figure 
3.2, F-G). 
8. The CCA, external carotid artery (ECA) and internal carotid artery (ICA) are exposed 
and mobilized from the surrounding tissues to near the skull base. The vagus nerve (X 
nerve) is sharply dissected from the CCA and ICA (Figure 3.2, H).  
9. The occipital artery (OA), a branch of the ECA, is coagulated. Other branches of the 
ECA including superior thyroid (STA) and ascending pharyngeal arteries are 
cauterized (Figure 3.2, I). This allows greater ease in mobilizing the larger vessels. 
10. Further dissection of the ICA identifies the glossopharyngeal nerve (IX nerve) near the 
origin of the pterygopalatine artery (PPA), which is ligated close to its origin with a 
McEnzie clip (Figure 3.2, J). At this point, the ICA is the only remaining branch of the 
CCA. 
11. A 6-0 loose silk knot is left at the beginning of the ECA stump, near the bifurcation 
(Figure 3.2, K).  
12. The ECA is further dissected, tied off as distally as possible with 6-0 silk suture and 
McEnzie surgical clip and then cut. The ECA terminal stump, about 5 mm long from 
the ECA-ICA bifurcation, is freed from surrounding tissue (Figure 3.2, L-M).  
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 13. Microvascular clips are place on CCA and ICA and a small arteriotomy is made with 
spring scissors in the ECA stump, distal to the loose knot (Figure 3.2, N).  
14. A 4-0 nylon silicone rubber-coated tip monofilament (Doccol Corporation, Sharon, 
MA, USA) is then gently inserted into the ECA stump towards the ICA. The loose silk 
suture around the ECA stump/intraluminal nylon filament is tightened to prevent 
bleeding (Figure 3.2, O). 
15. Microvascular clips are removed from both the CCA and ICA and the filament is then 
slowly advanced about 19 to 21 mm from the fork. While advancing the filament, a 
slight resistance may be felt and laser-Doppler flowmetry (LDF) should confirm a 
sudden decrease to less than 30% of baseline values when the blunted tip of the 
filament has blocked the origin of the MCA and reached the proximal segment of the 
ACA (Figure 3.2, P-Q). At this point, the intraluminal filament is blocking the origin 
of the MCA, occluding all sources of blood flow from the ICA, ACA, and posterior 
communicating artery. About 7-10 mm length of the filament remains outside, to be 
withdrawn to allow reperfusion.  
16. The timer is started and ischemia persists for 60 minutes, until the thread is withdrawn. 
The operational sequence for reestablishing the blood flow in the MCA is to slowly 
retract the intraluminal filament, loosen the silk knot, withdraw the filament and 
quickly apply a McEnzie clip to the stump of the ECA to block blood flow. LDF 
should confirm reperfusion.  
17. The skin incision is closed with a continuous 2-0 silk suture, and the animal is placed 
in a clean cage. CBF values are measured throughout recovery period. 
18. One milliliter of pre-warmed sterile saline is administered IP to provide hydration 
during recovery stage.  
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Figure 3.2. Step-by-step MCA I-R surgical technique. A, The bregma is located 
at the junction of the sagittal and coronal sutures. The blue dot located 2 mm 
posterior and 3.5 mm right lateral the bregma spots the point for drilling. B, 2 mm 
drill hole down to the dura-mater. C, Laser-Doppler probe holder glued to the 
bone. D, Laser-Doppler probe attachment to probe holder. E, Rat positioned in 
supine and limbs fixed. F, Skin incision and retraction to expose ventral cervical 
muscles. G, Retraction of cervical muscles to expose CCA, ECA, STA, trachea 
and vagus (X) nerve. H, STA and ascending pharyngeal artery exposed to 
diathermia and further dissection expose CCA fork, ICA, ECA, OA and 
glossopharyngeal (IX) nerve. I, OA cauterized and digastric muscle retracted to 
expose ICA and its collateral PPA. J, A McEnzie clip inserted to ligate the PPA. 
K, 6-0 silk loose knot left at the origin of the ECA. L, ECA ligated as distally as 
possible with the use of 6-0 silk knot and McEnzie clip. M, ECA cut and stump 
exposed. N, Transient microvascular clips applied on both CCA and ICA. O, A 
small ECA arteriotomy and 4-0 nylon monofilament insertion in the artery. The 
loose knot is tightened to prevent bleeding and the ICA clip removed. The white 
silicone rubber-coated tip can be seen inside the ICA. P, Removal of CCA clip. 
Q, The monofilament is carefully introduced until a drop in the baseline of the 
CBF is noticed (inner figure). CCA, common carotid artery; ECA, external carotid 
artery; ICA, internal carotid artery; OA, occipital artery; PPA, pterygopalatine 
artery; STA, superior thyroid artery.  
 
Throughout recovery period, animals are left in a cage with full water and food access. 
 
 
3.2.2 Cortical Blood Flow Measurements 
Cortical CBF was monitored by LDF (Periflux System 4000, Probe 407, Perimed-
Instruments, Stockholm, Sweden) before, during occlusion, and within 1 hour of reperfusion. 
As previously explained, a small burr hole was drilled 2 mm posterior to the bregma and 3.5 
mm lateral to the midline and the micro-Doppler probe positioned above the dura in a micro-
holder glued to the bone. Probe placement allows the specific measuring of a small amount of 
tissue focused on the right MCA. Steady-state baseline values were recorded before 
occlusion, and the CBF measured during occlusion and reperfusion was expressed as a 
percentage of the baseline values (Figure 3.3).  
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Figure 3.3. Representative images of CBF monitoring patterns during induction 
of ischemia and reperfusion phases of surgical procedure. A, CBF monitoring 
during MCAO. (a) clipping of CCA and ICA for ECA arteriotomy and filament 
intraluminal introduction, (b) clips removal for filament progressing, (c) sudden 
intraluminal MCAO with corresponding CBF value drop. B, CBF monitoring 
during MCA reperfusion. (d) filament retraction initiates reperfusion, (e) filament 
intraluminal removal from the ICA results in an additional slope in the CBF 
suggesting complete reperfusion.  
 
Some CBF criteria indicate successful MCAO: 
1. CBF decreases to less than 30% during period of intraluminal MCAO - baseline CBF 
is set at 100% before insertion of suture into ICA; 
2. CBF remains at this low level during entire occlusion time; 
3. CBF recovers to over 80% of baseline within 30 minutes of filament withdrawal. 
 
Rats with CBF patterns suggesting subarachnoid hemorrhage, incomplete ischemia or 
incomplete reperfusion were excluded (Figure 3.4). 
 
Figure 3.4. Subarachnoid hemorrhage. A, Representative CBF pattern 
suggesting SAH. (a) slow decrease on CBF while introducing the intraluminal 
thread through the ICA, in relation with its rupture and succeeding SAH. B, 
Brain with evidence of SAH. 
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 3.2.3 Neurological Examination 
At 24-hour, a nine-point neurological scale (0=normal to 9=highest handicap) was 
implemented115. Four tests were performed in order to assess spontaneous activity, laterality 
in movement, resistance to left forepaw stretching and parachute reflex (Table 3.1). Scores 
obtained for each test were added to obtain the final neurological score. 
 
Table 3.1 Scale neurological evaluation used at 24-hour into reperfusion 
Neurological assessment 
Item 
score 
A. Spontaneous activity 0-2 
Moving/exploring 
Moving without exploration 
No displacement 
 0 
 1 
 2 
B. Laterality in movement   0-3 
Symmetrical  
Left drifting when elevated by the tail 
Spontaneous left drifting 
Circling to the left  
 0 
 1 
 2 
 3 
C. Resistance to left forepaw stretching 
No stretching allowed 
Stretching allowed 
No resistance 
D. Parachute reflex 
0-2 
 0 
 1 
 2 
0-2 
Symmetrical 
Asymmetrical 
 0 
 1 
Contralateral forelimb retracted  2 
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 3.2.4 Infarct Volume and Brain Edema Assessment 
At 24 hours into reperfusion, animals were euthanized with anesthetic overdose. The brains 
were removed, placed in a brain matrix (World Precision Instrument, Hertfordshire, UK) and 
sliced in 2-mm thick coronal sections, beginning 2 mm from the frontal pole and ending 
rostral to the corticocerebellar junction, resulting in 6 slices per animal (Figure 3.5, A-B).  
 
The sections were then stained in 2% TTC (Sigma-Aldrich, St. Louis, MO, USA) saline 
solution for 10 minutes at 37°C in the dark. The staining action of TTC is based on the 
oxidation of TTC by intact mitochondrial dehydrogenase, which oxidizes the tetrazolium salts 
into formazan, a carmine red product. Accumulation of the red formazan stains the tissues red, 
and the intensity of the red color is proportional to the rate of respiration in those tissues123. 
Due to the absence of active dehydrogenase in the infarcted or necrotic tissue, it remains 
unstained. Therefore, this method can distinguish live (stained red) from infarct (unstained 
white) tissue. TTC stain demonstrates ischemic lesions that can be appreciated visually even 
without microscopic examination and enables assessment of lesion size with minimal tissue 
preparation (Figure 3.5, C-D). Quantitative measurements of infarct volume determined by 
this method have proven useful in determining the extent of brain injury in experimental 
stroke models and in assessing potential neuroprotective agents for cerebral ischemia. The 
brain sections were next fixed in 4% paraformaldehyde at 4°C overnight. The fixed brain 
tissue sections were then digitally scanned and analyzed with ImageJ software version 1.45 
(Figure 3.5, E-F).  
 
Total brain infarct volume was calculated by summing the infarct area of all brain slices (area 
of infarct in square millimeters x thickness [2 mm]). The amount of infarction was expressed 
both in absolute terms in cubic millimeters and as a percentage of contralateral hemisphere 
adjusted for brain edema, thereby avoiding the distortion caused by edema and surrounding 
white matter124. Therefore, a corrected infarct volume by computing the volume of the left 
and right hemispheres and applying the following formula was calculated, where LHV=total 
left hemisphere volume, RHV=total right hemisphere volume and InfV=measured infarct 
volume:  
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Figure 3.5 Infarct and brain edema assessment technique. A, Brain removed 
from the cranium. B, Brain matrix for adult rat brains for standard 1 or 2 mm-
coronal brain slicing. C, Representation of six coronal rat brain sections (24-
hour reperfusion after 60-minute MCAO). D, Brain tissue slices are soaked in 
2% TTC solution in a plastic dish for around 15 minutes. When tissue turns 
pinkish with white (unstained) regions, it is ready to fix. E, Representative image 
of scanned brain TTC-stained sections. F, Infarct area digitally demarcated for 
infarct and brain edema measurements. 
 
The edema index, that is, the space-occupying effect was also calculated with the use of the 
equation described below and expressed as the percentage of volume increase of the injured 
hemisphere: 
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For each single experiment, a data extraction form was filled (Figure 3.6) 
 
 
Figure 3.6 Data extraction form. 
 
31
 3.2.5 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software version 6.0. Parametric 
data were analyzed using Student’s t-test for single comparisons between groups and non-
parametric data (neurologic scores) were subjected to the two-tailed Mann-Whitney test, 
unless stated. Data are presented as mean±standard error of the mean (SEM) for n 
observations, where n represents the number of animals studied. A p value of less than or 
equal to 0.05 was the threshold considered to be a statistically significant difference or 
association. 
 
 
3.3 Results 
 
In order to assess the validity of the model, three groups with consecutive rats were 
performed: sham group, I-R 60’ group (60-minute ischemia followed by 24-hour reperfusion), 
and I-R 90’ (90-minute ischemia followed by 24 hour reperfusion).  
 
From the thirteen consecutive rats anesthetized with pentobarbital undergoing transient MCA 
ischemia of 60 minutes, I-R 60’ group, 8 rats were included in the analysis. The reasons for 
exclusion of 5 individuals were: evidence of subarachnoid hemorrhage (2), incomplete 
reperfusion according to LDF criteria (2), and unexplained mortality at 24-hour reperfusion 
(1). Table 3.2 details main endpoint results for this group. Overall mortality was 7,7%. 
 
Table 3.2 I-R 60’ group main endpoint results (n=8) 
 Mean SEM Minimum Maximum 
Neurological grade 6,38 0.32 5 8 
Infarct volume (mm3) 202,9 18,3 151,7 293,3 
Infarct proportion (%) 24,6 3,1 16,2 40,9 
Brain edema (%) 8,09 1,39 2,07 12,20 
Initial weight (g) 322 7,3 298 350 
Final weight (g) 285 7,0 262 312 
Weight loss (%) 11,5 0,55 9,1 14,2 
 SEM, standard error of the mean. 
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 Ten consecutive rats anesthetized with pentobarbital undergoing transient MCA ischemia of 
90 minutes, I-R 90’ group, were then performed. Three individuals were excluded due to: 
mortality at 24 hours (2) and incomplete reperfusion according to LDF criteria (1). Table 3.3 
details main endpoint results for I-R 90’ group. Overall mortality was 20%. 
 
Table 3.3 I-R 90’ group main endpoint results (n=7) 
 Mean SEM Minimum Maximum 
Neurological grade 7,14 0.46 5 9 
Infarct volume (mm3) 216,9 10,2 181,3 245,9 
Infarct proportion (%) 27,3 1,4 22,2 31,4 
Brain edema (%) 7,52 0,82 4,90 9,92 
Initial weight (g) 313 7,2 282 343 
Final weight (g) 275 7,9 244 312 
Weight loss (%) 12,3 0,78 9,0 15,5 
 SEM, standard error of the mean. 
 
A group of three sham rats anesthetized with pentobarbital was also constituted, in which the 
entire surgical procedure as with I-R was performed except for the filament introduction. No 
exclusions were necessary. Table 3.4 details main endpoint results for this group. The 3 
animals in the sham group presented no evidence of brain infarct and measured edema was 
insignificant. There was no mortality in this group. 
 
Table 3.4 Sham group main endpoint results (n=3) 
 Mean SEM Minimum Maximum 
Neurological grade 0,33 0,33 0 1 
Infarct volume (mm3) 0 0 0 0 
Infarct proportion (%) 0 0 0 0 
Brain edema (%) 0,09 0,46 -0,74 0,86 
Initial weight (g) 301 4,0 294 308 
Final weight (g) 269 2,9 263 272 
Weight loss (%) 10,7 0,70 9,6 12,0 
 SEM, standard error of the mean. 
 
Simple comparisons between the groups were performed to assess the internal validity of the 
model. Comparison between pre-operative weight, at 24-hour, and percentage of weight loss 
were made with no differences between groups (Figure 3.7).  
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Figure 3.7 Bar graph comparing the weight before surgery and at 24-hour 
reperfusion for each group. No significant differences between initial and final 
weights were found between the three groups. Data represent the mean±SEM, 
2-way ANOVA.   
 
Infarct volume was significantly smaller in I-R 60’ compared to IR 90’ group (24,62±3,08 
compared to 27,30±1,35, p=0.044) (Figs. 3.8 and 3.9).  
 
Figure 3.8 Bar graph comparing total infarct volume between groups. Infarct 
volumes are presented as percentages of the total contralateral hemisphere 
volume. Data represent the mean±SEM *p<0.05, Student’s t-test. 
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Figure 3.9 Representative images of TTC-stained coronal brain sections of 
sham, 60’ I-R, 90’ I-R and permanent ischemia rats.  
 
 
Nissl bodies-stained sections were performed in a pilot-study rat brain submitted to MCA I-R 
of 60 minutes followed by 24-hour reperfusion to compare neuronal population between 
hemispheres (Figure 3.10). 
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Figure 3.10. Photomicrographs Nissl bodies stain brain sections of I-R 60’ pilot-
study rat. A, Whole brain section images. B, Cerebrovascular changes in the 
infarct area of ipsilateral compared to contralateral hemisphere: ipsilateral 
ischemic area reveals predominance of dead or dying neurons as shown by the 
lower number of neurons and their picnotic nucleus.  
 
Hemispheric edema was non-significant between ischemic groups (8,09±1,39 in I-R 60’ 
group compared to 7,52±0,82 I-R 90’ group) (Figure 3.11).  
 
Figure 3.11 Bar graph depicting the percentage of hemispheric edema for each 
group. No significant differences were found between I-R 60’ and I-R 90’ 
groups. Data represent the mean±SEM 
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 Neurologic assessment showed no difference between 60-minute or 90-minute MCA ischemia 
groups (Figure 3.12). 
 
Figure 3.12 Scatter plot showing the 9-point neurologic score results at 24 
hours for each group. Open circles indicate values for individual animals. 
Horizontal bars indicate group median values. No significant differences were 
found between two ischemic groups, Mann-Whitney test.  
 
 
3.4 Discussion and Conclusions 
 
There is evidence that not only duration of ischemia influences infarct volume in this animal 
model, but also the differences in animal strain, size, cerebrovascular anatomy, temperature, 
anesthesia, duration of reperfusion, and type of suture.  
 
Our protocol for using Wistar rats in a focal cerebral MCA ischemia followed by 24-hour 
reperfusion was mainly based on two assumptions: 
• Wistar rats are preferred by some to Sprague-Dawley due to their higher susceptibility 
to infarction and reperfusion injury after MCAO125. Wistar strain also exhibits better 
survival rates after transient MCAO126. 
• Reglodi studied the evolution of infarct size at 4, 8, 12, 24, 48, and 72 hours after 
MCAO and found: infarct size gradually increased; individual response to the 
ischemic injury was very different during the first 12 hours; infarct volume peaked at 
24 hours; and no significant difference could be demonstrated between the infarct 
sizes after 24, 48, or 72 hours127. 
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Several anesthetics have been used. Pentobarbital has been shown to have protective 
characteristics in cerebral I-R rodent models128. Also, volatile anesthetics appear to temporally 
reduce ischemic cerebral injury during the early stage of reperfusion and, for example, 
isoflurane was reported to provide protection against transient focal ischemia129. During the 
setting up and establishment of the model we used pentobarbital (60 mg/kg) IP. In the 
following phase of this research, however, we have changed to a ketamine (80 mg/kg) and 
xilazine (8 mg/kg) mixture IP which, for legal issues, was initially not available and required 
the National Authority of Medicines and Health Products’ authorization.  
 
Traditionally, intraluminal sutures used to occlude the MCA are prepared by flame-rounding a 
3- or 4-0 nylon suture tip. This procedure produce sutures with varying tip diameters and thus, 
requires several attempts at occlusion before finding a suture that matches the vessel diameter 
of a given rat. After some discouraging experiments with these flame-rounded filaments, it 
was decided to use commercially prepared silicon-coated 4-0 nylon filaments (Doccol 
Corporation, MA, USA) as it raised the success rate by providing better occlusion without 
increasing SAH.  
 
Clearly, the experience of the researcher is a key factor. For instance, factors such as duration 
of surgery, adequate dissection and retraction of tissues, sparing blood losses, and perception 
of resistance to the thread’s progress are highly dependent on training and directly related to 
the outcome. From the beginning, we have persistently searched for measures to reduce 
heterogeneity of groups: defining inclusion and exclusion criteria (gender, weight, LDF 
patterns, evidence of SAH), strictly controlling the body temperature, performing a fine step-
by-step surgical technique, using a similar filament in all animals and standardizing endpoint 
evaluations. 
 
Consistency and predictability of results are far more important than absolute values of infarct 
volume. Nevertheless, the following table is a non-exhaustive results review from several 
research groups for infarct volumes in adult untreated male Wistar rats evaluated with TTC at 
24-hour reperfusion, after transient intraluminal MCA ischemia (Table 3.5). 
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 Table 3.5 Previously published infarct volumes at 24-hour reperfusion after 
intraluminal transient MCAO among untreated rats. Data is presented as 
mean±SD, unless SEM stated 
Author Body weight (g)* Anesthesia Suture size MCAO (min) Infarct volume
# 
Calloni 2010130 
423±42 
439+-46 
Halotane 5-0 
90 
120 
162.9±110.8 
259.3±125.1 
Mouw 2002131 250-330 Halotane 4-0 180 134.6±108.9 
Alkayed 1998132 255-360 Halotane 4-0 120 25.7%±6.8%, SEM 
Johnson 1998133 260-310 Halotane 
3-0 + 
poly-L-lysine 
180 22.8%+-2.8%, SEM 
Hayashi 1998134 250-280 Pentobarbital 4-0 + silicone 90 33.2%±4.2% 
Present study  
322±21 
 
 
313±19 
Pentobarbital 4-0 + silicone 
60 
 
 
 
90 
202.9±51.8 
24.6%±3.1%, SEM 
24.6%±8.7% 
 
216.8±27.0 
27.3%±1.4%, SEM 
27.3%±3.6% 
SD, standard deviation; SEM, standard error of the mean; MCAO, middle cerebral artery occlusion 
* mean±SD and/or minimum-maximum, as described by original authors 
# mean±SD (mm3) and/or percentage total volume of ipsilateral hemisphere, as described by original authors 
 
 
 
 
Despite difficulty in comparing endpoints between different research groups, as there are 
different variables to consider, overall, results from the present study, including deviations, 
are in accordance with the previous ones, that lead us to conclude the establishment of the 
model was accomplished.  
 
The following figure summarizes the timeline for the acute phase of experiments detailed in 
next chapters, which included control and treatment groups – rhEPO and TDZD-8 groups 
(Figure 3.13). 
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Figure 3.13. Study flow diagram of experiments depicting the course of 
experimental ischemia, timing of drug administration and monitoring. In all drug-
treated groups a bolus of the selected drug was administered prior to ischemia. 
NSE, neuron specific enolase.  
 
 
As shown, drug experiments were planned to comprise a 60-minute period ischemia rather 
than 90-minute ischemia, since I-R 60’ group showed both lower mortality and an adequate 
amount of infarct volume/hemispheric edema to assess changes with drugs.  
 
 
Due to timing, technical and financial constraints, some endpoints that were not evaluated 
during the setting up of the model could, however, be performed during the drug evaluation 
experiments phase. In accordance with STAIR preclinical recommendations109,110, these 
additional endpoints included histological, biomarkers, immunohistochemical, and western 
blot procedures that will be detailed in corresponding sections. 
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 4   NEUROPROTECTIVE EFFECTS OF ERYTHROPOIETIN 
 
4.1 Background 
 
Erythropoietin (EPO) is a natural hormone most notably recognized for its central role in 
erythropoiesis and successfully used for anemia treatment in the last two decades. Fetal liver, 
and postpartum kidney are the two major sites of synthesis. The finding that EPO and its 
receptor (EPOR) are expressed throughout the brain in glial cells, neurons, and endothelial 
cells, suggested that this glycoprotein could have hematopoiesis-independent effects on the 
nervous system135,136. Endogenously produced EPO and/or expression of the EPOR gives rise 
to autocrine and paracrine signaling in different organs particularly during hypoxia, toxicity 
and injury conditions. EPO mRNA levels have been shown to remain elevated in the brain for 
more than 24 hours during the duration of the hypoxic stimuli137 and following 
ischemic/hypoxic injury, dramatic changes have been reported in the expression of EPO and 
its receptor within and around infarcts in human brain regions138. 
 
EPO is one of the gene products of HIF-1 and an increase in HIF in brain tissue after hypoxia 
has been demonstrated in several rodent models84. EPO binds the EPOR to initiate an auto-
phosphorylation of the receptor-associated Janus kinase-2 that leads to 
phosphorylation/activation of several downstream signal cascades critical to regulate a variety 
of cell functions such as ionic balance, neurotransmitter synthesis and cell survival139-141 
(Figure 4.1).  
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Figure 4.1. Neuroprotective signaling pathways employed by EPO. During 
hypoxia, HIF-1 is activated which induces the transcription of endogenous EPO. 
Endogenous and exogenous EPO binds the extra-cellular EPOR and JAK2 is 
phosphorylated leading to several downstream signaling pathways including 
MAPK, STAT5, NF-κB and the PI3K. Activated MAPK and NF-κB translocate 
into the nucleus and initiate transcription of genes encoding for proteins 
involved in the response to stress, including several molecules that regulate 
apoptosis and inflammation. STAT5 also translocates into the nucleus and 
triggers transcriptional activation of several genes encoding for anti-apoptotic 
molecules, such as Bcl-2 and Bcl-xL. Several apoptotic stimuli may trigger 
cytochrome c release from mitochondria to the cytosol to activate caspase 
cascade, which commits the cell to the death process. PI3K activation leads to 
Akt phosphorylation which inhibits GSK-3β and subsequent mitochondrial 
apoptotic initiator caspase-9 expression. Furthermore, phosphorylated-Akt also 
translocates into nucleus and induces cell survival genes transcription, activates 
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 NF-κB and inhibits pro-apoptotic molecules such as BAX and BAD. Binding of 
EPO to its receptor on the endothelial cells leads to activation of PI3K/Akt 
pathway, causing activation of eNOS, which decreases ROS and an increase in 
NO production resulting in cerebral vasodilatation. Lines with arrows indicate 
activation and lines with flattened ends represent inhibitory effects. Akt, protein 
kinase B; BAD, Bcl-2-associated death promoter; BAX, Bcl-2-associated X 
protein; Bcl-2, B-cell lymphoma 2; eNOS, endothelial nitric oxide synthase; 
EPO, Erythropoietin; EPOR, erythropoietin receptor; GSK-3β, glycogen 
synthase kinase-3β; HIF-1, Hypoxia-inducible factor-1; JAK2, Janus-tyrosine 
kinase 2; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor-κB; 
PI3K, phosphoinositide 3-kinase; rhEPO, recombinant human erythropoietin; 
ROS, reactive oxygen species; STAT5, signal transducer and activator of 
transcription.  
 
Several preclinical studies have shown protective and reparative effects of EPO for 
neurovascular unit following an I-R injury and that this hormone may work for the response 
in different timepoints and through indirect effects (Figure 4.2). Moreover, under ischemic 
conditions, in vitro and in vivo research has implicated EPO in neurogenesis regulating the 
production of neuronal progenitors by mammalian forebrain neural stem cells142. 
 
 
Figure 4.2. Schematic representation of possible EPO neuroprotection acute 
and long term effects. BBB, blood-brain barrier. 
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 Preclinical research has also shown that a high-dose of systemically administered rhEPO 
crosses the BBB, leading to neuroprotective and neurotrophic effects143-145. As a result, 
several trials are currently ongoing to identify possible benefits in the usage of rhEPO for 
specific clinical situations requiring neuroprotection146-148. To our knowledge, we present the 
first animal study based on a MCA I-R model aiming to investigate the potential benefits of a 
single dose of 1.000 IU/kg intravenous rhEPO as a possible pretreatment against neuronal 
damage in neurovascular procedures that require transient cerebral artery occlusion. Research 
on translational pharmacokinetics showed that rhEPO 1.000 IU/kg per dose IV for neonatal 
encephalopathy149 and for extremely low birth weight infants150 reach drug exposure levels 
that afford optimal neuroprotection in animal models, and concluded this moderate dose is 
likely to minimize risks associated with a higher dose. Furthermore, selected dose and route 
has been used in several clinical trials with no additional safety concerns reported and thus, 
could be safely translated to the clinical setting151-153.  
 
 
 
4.2 Materials and Methods 	  
A total of 28 adult male Wistar rats (240-340 g) housed under diurnal light conditions with 
unlimited access to food and water were used (n=14 per group).  
 
4.2.1 Intervention 
Treatment group had rhEPO (epoietin β, F.Hoffmann-La Roche, Basel, Switzerland) 
administered at a dose of 1000 IU/kg IV in the tail vein, 10 minutes prior to the ischemia 
onset. Control group had the same volume of saline administered similarly. Allocation 
concealment was attained by having drug or saline individually prepared and labeled for each 
animal according to randomization by an independent investigator. The principal investigator, 
blinded to treatment, carried out all surgical procedures. 
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 4.2.2 Middle Cerebral Artery Ischemia-Reperfusion 
Rats were food deprived 12 hours prior to surgery. Anesthesia was induced by IP 
administration of ketamine (80 mg/kg) and xylazine (8 mg/kg) mixture, supplemented as 
needed. Anesthetized rats were placed onto a thermostatically controlled heating pad, a rectal 
probe was inserted, and body temperature was monitored and maintained between 36.5°C and 
37.5°C. Cerebral blood flow was monitored by LDF in the supply territory of the right MCA 
as previously detailed. Transient focal cerebral ischemia was induced by 60-minute right 
MCA occlusion followed by 24-hour reperfusion, as previously described (Figure 3.2). 
Briefly, the right CCA, ICA and ECA were exposed under the operating microscope and 
isolated from branches through a midline neck incision. The ECA was tied and cut at 
approximately 5 mm from the bifurcation and a loose 6-0 silk knot was placed around the 
ECA origin. After, microvascular clips were placed on the CCA and ICA, an ECA stump 
arteriotomy distal to the loose knot was performed and a 4-0 nylon silicone rubber-coated tip 
monofilament was inserted. The suture around the ECA stump and the intraluminal nylon 
filament was tightened to prevent bleeding and the clips were removed. The filament was 
gently introduced (19-21 mm) into the ICA to the level where the MCA branches out, until 
LDF signal decreased to less than 30% of baseline, occluding the right MCA at its origin at 
the circle of Willis. After a 60-minute period of ischemia, the thread was cautiously removed 
reestablishing the blood flow in the MCA. The ECA was permanently ligated at the level of 
bifurcation. Animals were allowed to recover.  
 
Rats with CBF patterns suggesting subarachnoid hemorrhage, incomplete ischemia (CBF does 
not decrease to a maximum of 30% of baseline) or incomplete reperfusion (CBF does not 
recover to over 80% of baseline within 30 minutes of filament withdrawal) were excluded and 
replaced. 
 
4.2.3 Neurological Examination 
At 24-hour into reperfusion, the previously described nine-point neurological scale (0=normal 
to 9=highest handicap (Table 3.1) was performed in the rats by the principal investigator, who 
was blinded to the treatment groups. Animals were then euthanized with anesthetic overdose. 
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 4.2.4 Infarct Volume and Brain Edema Assessment 
To calculate the minimum sample size for infarct volume continuous variable, the formula 
n=1+2C(s/d)2 was used154, where ‘s’ is the estimate of the population standard deviation of 
the variable, ‘d’ corresponds to the effect size and ‘C’ is dependent on values for significance 
level (α) and power (1-β). Using a conservative approach, with a significance of p=0.01, a 
power of 90% (C=14.88), a SD for the infarct volume estimated from the pilot study of 9% 
(8.7%; for details, see Table 3.5) and a magnitude of the effect size to detect of 20%, a 
minimum of 8 rats per group (n=7.03) would be needed before the final infarct volume 
assessment.  
 
As detailed in a previous chapter, brains were removed, placed in a brain matrix and sliced in 
2-mm thick coronal sections, resulting in 6 slices per animal (n=8 per group). The sections 
were stained in 2% 2,3,5-TTC saline solution for 10 minutes at 37°C in the dark and fixed in 
4% paraformaldehyde at 4°C overnight. Sections were scanned and analyzed using ImageJ 
software version 1.45. Brain infarction was visualized as areas of unstained (white) tissue, 
which contrasted from brick red stained areas of viable tissue. Summing the infarct area of 
each coronal slice and multiplying that number by the thickness of the sections allowed the 
calculation of the total infarct volume. Right and left hemispheric volumes were calculated 
similarly. The amount of infarction was expressed in absolute terms in cubic millimeters and 
as a percentage of contralateral hemisphere adjusted for brain edema124. An index of brain 
edema was assessed by calculating the percent increase of size of the ipsilateral (injured) 
hemisphere compared with the contralateral (uninjured) hemisphere. The described analysis 
was performed blindly to individual treatment by the principal investigator. 
 
4.2.5 Determination of Neuron-Specific Enolase (NSE) Plasma Levels 
Blood samples were taken by puncture of the left cardiac ventricle prior to sacrifice.  Blood 
was centrifuged at 10.000 rpm for 10 minutes and the isolated serum was frozen and stored 
until time of assay. Plasma NSE measurements were performed with an 
electrochemiluminescence immunoassay, using a sandwich technique with double 
monoclonal antibodies directed against NSE (Roche Diagnostics, Mannheim, Germany) and 
an Elecsys 2010 analyzer (Roche Diagnostics, Mannheim, Germany). Data were normalized 
to nanograms per mililiter of plasma. 
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 4.2.6 Histology and Immunohistochemistry Procedures 
Rat brains were removed, ﬁxed in 4% paraformaldehyde in phosphate buffered saline (PBS) 
for 72 hours at room temperature, dehydrated through a graded ethanol series and embedded 
in paraffin (n=3 per group). H&E staining was performed as previously described155 and 
images were acquired using a brigthfield Axioscop microscope (Zeiss, Göttingen, Germany). 
For Fluoro-Jade staining, 6 µm thick coronal sections were deparaffinized and rehydrated. 
Slides were first immersed in 100% alcohol for 3 minutes followed by 1 minute in 70% 
alcohol and 1 minute in distilled water. The slides were then transferred to a solution of 
0.06% potassium permanganate for 15 minutes on a shaker table and protected from light. 
After, the slides were rinsed in distilled water for 1 minute and immersed in Fluoro-Jade B 
(Chemicon, CA, USA) staining solution 0.001% for 30 minutes with moderate agitation. 
Slides were rinsed for one minute in each of three distilled water washes and dried at room 
temperature. The dry slides were cleared by immersion in xylene for at least a minute before 
coverslipping with DPX (Fluka, WI, USA, or Sigma-Aldrich, MO, USA). The tissue was then 
examined using an epifluorescent AxioScope microscope (Zeiss, Göttingen, Germany) with 
blue (450-490 nm) excitation light. The number of positive Fluoro-Jade B neurons were 
counted in 4 sections of 0.16 µm2 (n=3 per group) within the region of interest using ImageJ 
software version 1.45 and expressed as positive cells/section. A single blinded observer 
performed the analysis described. 
 
For immunostaining, 6 µm thick coronal sections were submitted to antigen retrieval in 20 
mM citrate buffer with 1.5% H2O2 for 15 minutes at room temperature in the dark, incubated 
for 10 minutes in Tris/EDTA buffer at 84°C and blocked for 1 hour at room temperature in 
1% bovine serum albumin (BSA) in PBS. Primary antibody, rabbit anti-p-Akt (1:100, 
CellSignaling Technology, MA, USA) was used in 0.5% BSA in PBS overnight at 4°C. After 
washing in PBS, sections were incubated for 1 hour at room temperature with antibodies anti-
rabbit coupled to AlexaFluor 568 (#A11077, 1:1000, Invitrogen, CA, USA) in 0.5% BSA in 
PBS, incubated for 20 minutes in 4,6-diamidino-2-phenylindole (DAPI) and mounted with 
Shandon Immu-Mount™ Aqueous Non-fluorescing Mounting Medium (Thermo Scientific, 
IL, USA). Tissue sections were visualized with an epifluorescent AxioScope microscope 
(Zeiss, Göttingen, Germany) and the number of total nuclei (DAPI staining) and the ones 
positive for p-Akt were counted to present the results as percentage of p-Akt-positive nuclei 
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 (2 sections within the region of interest, n=3 per group). A single blinded observer performed 
the analysis described. 
 
 
4.2.7 Western Blot Analysis 
For western blot analysis (N=3 per group), frozen tissue samples cells were lysed in a 
radioimmunoprecipitation assay (RIPA) buffer containing Tris 50 mM (pH 8.0), 5 mM EDTA 
(pH 8.0), 150 mM NaCl, 1% NP-40, 10% glycerol and 0.1% sodium dodecyl sulfate, and 
sonicated for 20 seconds. The lysate was centrifuged at 14.000 g for 10 minutes at 4ºC and the 
supernatants were collected and stored at -80ºC. Protein concentrations were determined using 
Nanodrop ND-1000. Cell extracts containing equal amounts of protein (100-150 µg) were 
separated on sodium dodecyl sulphate-polyacrylamide gel electrophoresis and transferred to a 
nitrocellulose membrane. The membranes were blocked with 5% non-fat milk, incubated with 
the primary antibody overnight at 4ºC (anti-rabbit p-Akt [1:1000, #12178, Cell Signaling, 
MA, USA] and anti-rabbit Akt [1:1000, #4691, Cell Signaling, MA, USA]), and then with a 
horseradish peroxidase-labeled secondary antibody for 1 hour at room temperature. After 
extensive washes, immunoreactive bands were detected by LumiGLO® (Cell Signaling, MA, 
USA) and visualized by autoradiography with Hyperfilm ECL. Phosphorylation levels of Akt 
were analyzed by the ratio of p-Akt to total Akt levels and expressed as fold change compared 
to contralateral MCAO hemisphere. 
 
4.2.8 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software version 6.0. Parametric 
data were analyzed using Student’s t-test for single comparisons between groups and non-
parametric data (neurologic scores) were subjected to the two-tailed Mann-Whitney test. Data 
are presented as mean±SEM for n observations, where n represents the number of animals 
studied. For histological scoring and western blot analysis, each data point represents analyses 
of brain sections taken from 3 individual rats. A p value of less than or equal to 0.05 was the 
threshold considered for a statistically significant difference or association. 
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 4.3 Results 
 
All animals lost between 10 to 18% of body weight during the 24-hour recovery period with 
no significant differences between groups. Normothermia was maintained in all animals. 
There were no significant differences between groups with respect to CBF pattern and 
glycemia values during the procedure. 
 
Results showed no difference between groups in the infarct volume. The total brain infarct 
volume was 265,46±13,88 mm3 for the control group and 223,33±12,97 mm3 for the treatment 
group. Expressed as a percentage124, infarct volume was 28,02±1,73% in the control group 
and 25,71±1,41% in the rhEPO group (Figure 4.3).  
 
 
Figure 4.3. Bar graph comparing total infarct volume between control and 
rhEPO-treated groups. Infarct volumes are presented as percentages of the 
contralateral hemisphere. Data represent the mean±SEM (n=8 per group). 
Differences between groups were not significant (p=0,32). 
 
 
Also, the number of positive Fluoro-Jade degenerating neurons in the interest area was similar 
between groups (Figure 4.4).  
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Figure 4.4. Comparison of degenerating neurons in both control and rhEPO-
treated groups. A, Representative images of brain section stained for 
degenerating neurons using Fluoro-Jade, including both injured and 
contralateral hemispheres. Scale bar equals 20 µm. B, Bar graph comparing the 
number of positive Fluoro-Jade staining neurons per 0.16 µm2 in 4 sections for 
each rat of the interest area. Data represents the mean±SEM (4 sections for 
each individual, n=3 per group). Values were non-significant. 
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Brain swelling index was significantly decreased in treatment group when compared to 
control group (2,11±0,46% and 9,74±1,39%, respectively, p<0.001) (Figure 4.5).  
 
 
Figure 4.5. Bar graph depicting the percentage of hemispheric edema in both 
control and rhEPO-treated groups. Data represent the mean±SEM (n=8 per 
group). Values were significant, representing a 78% reduction of ipsilateral 
hemispheric edema in treatment group compared with control group. 
***p<0.001. 
 
 
Accordingly, H&E histological analysis of the brain parenchyma revealed neuropil spongiosis 
and perivascular edema, which was less marked in rhEPO-treated group (Figure 4.6).  
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Figure 4.6. Representative photomicrographs H&E brain sections of control and 
rhEPO-treated rats. A, Whole brain section images with delineated infarct area. 
B, Cerebrovascular changes in the infarct area: neuropil spongiosis (arrows) and 
perivascular edema (Ø) in control animals or its absence in rhEPO-treated ones 
(!). Contralateral hemispheres had no relevant changes. Scale bar equals 200 
µm. 
 
Treatment group had significantly lower NSE plasma levels compared with control group 
(1,17±0,07 ng/ml compared to 1,88±0,07 ng/ml respectively, p<0.001) (Figure 4.7), a relevant 
parameter for assessing the prognosis of cerebral hypoxia-ischemia, and presented 
significantly less neurological deficits (median value of 7,5 point in the neurological score 
compared to 5 point respectively, p<0.001) (Figure 4.8).  
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Figure 4.7. Bar graph showing a 38% reduction of NSE plasma levels at 24 
hours of reperfusion in the rhEPO-treated group. Data represent the 
mean±SEM (n=8 for control and n=13 for treatment group). ***p<0.001. 
 
 
 
 
Figure 4.8. Scatter plot showing the effects of rhEPO at 24 hours on a 9-point 
neurologic score (n=14 per group). Open circles indicate values for individual 
animals. Horizontal bars indicate group median values. RhEPO significantly 
reduced neurologic deficits. ***p<0.001, Mann-Whitney test. 
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Although it is believed that EPO activate/phosphorylate Akt, no differences between groups 
for p-Akt/Akt ratio in western blot and for percentage of p-Akt-positive nuclei in 
immunohistochemistry were found (Figs. 4.9 and 4.10). 
 
 
Figure 4.9. Western Blot showing expression of p-Akt and total Akt with a bar 
graph displaying the densitometric analysis of the relative intensity of p-Akt, 
normalized against total Akt. Data represent the mean±SEM (n=3 per group). 
Results did not show differences between groups. 
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Figure 4.10. Akt phosphorylation in control and rhEPO-treated groups. 
Representative images of the infarct area of the I-R injured and 
contralateral hemispheres after double staining for p-Akt and nuclear DAPI. 
Insert shows p-Akt zoom-in images. Merged images are also presented. 
Scale bar equals 50 µm. 
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 4.4 Discussion and Conclusions 
 
Our study reveals that rhEPO exerts protective effects in focal cerebral I-R. This is in line 
with rhEPO tissue protective effects described in several I-R injury animal models, as 
demonstrated by our research group156,157. RhEPO has been consistently tested at high doses 
(>5.000 IU/kg) in permanent cerebral artery occlusion rodent models and shown to be more 
effective when administered within 6 hours after stroke onset158. We investigated the effects 
of a single moderate dose of rhEPO as a pretreatment (1.000 IU/kg) in an I-R rodent model. 
This dose has been safely tested in humans151-153. Our results suggest that a single 1.000 IU/kg 
rhEPO IV administration just prior to a transitory occlusion of a cerebral artery may decrease 
secondary brain insult, resulting in a better neurological outcome.  
 
Regarding infarct volume outcome, we found no differences between groups at 24-hour 
reperfusion, although the improved neurological status and significantly lower NSE plasma 
levels observed at that point could indicate that this outcome may change in time between 
groups. NSE is an enzyme rapidly released by injured neurons. Lower NSE plasma levels in 
the treatment group may suggest a smaller penumbra area and a better clinical outcome. 
Plasma levels reach their maximum at 24 hours, and the best correlation between infarct size 
and plasma levels occurs at Day 3159. Plasma levels of this kinase have been found to be 
increased even before the onset of clinical symptoms and are strongly correlated with the 
clinical score and histological damage when clinical symptoms are present159. NSE plasma 
levels probably reflect neuronal cell death, suggesting that NSE is a reliable marker to follow 
neuronal damage160.  
 
Since its first description, Akt kinase has been gaining recognition as a key contributor to the 
cellular survival after neuronal injury161,162. There is evidence that EPO treatment activates 
this anti-apoptotic molecule163,164. Upon phosphorylation, the serine-threonine kinase Akt 
promotes cell survival by inactivating several targets, including GSK-3β, Bcl-2-associated 
death promoter (BAD) protein, Bcl-2-associated X protein (BAX) protein and caspase 9, or 
activates prosurvival molecules, suggesting that phosphoinositide 3-kinase (PI3K)/Akt/GSK-
3β pathway is involved in the neuroprotective effect of rhEPO163. Akt phosphorylation is 
coupled to its nuclear translocation where it phosphorylates nuclear targets, suppressing the 
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 transcription of death genes165. Unexpectedly, our results did not show an increase in the 
expression of p-Akt/Akt (western blot) or a p-Akt nuclear translocation 
(immunohistochemistry). The lack of PI3K/Akt/GSK-3β pathway activation could be 
explained by the use of lower rhEPO doses in our study when compared to previous ones. In 
fact, only up to 1% of systemically administered rhEPO crosses the BBB in primates145 and 
small penetration into the BBB is expected even when administering up to 10.000 IU/kg IV at 
single doses166. This poor crossing ratio suggests that high doses of systemically administered 
rhEPO are needed for direct neuron protective purposes. On the other hand, it has been 
demonstrated that EPO significantly provides neuroprotection following traumatic brain 
injury in EPOR-null mice, that is, even in the absence of erythropoietin receptor in the neural 
cells, probably mediated through vascular protection167. We postulate that the benefits 
observed in prophylactic rhEPO administration were not due to a direct neuronal action in the 
infarct area but the result of an indirect effect in brain swelling as a consequence of 
diminished BBB disruption. This is also in line with the histological findings and lack of 
difference between treatment and control groups on the number of positive Fluoro-Jade cells 
that labels degenerating neurons. 
 
Cerebral edema is a well-recognized factor for high morbidity and mortality in large territory 
ischemic strokes168. Brain edema following MCAO has been shown to gradually increase over 
the first 48 hours before peaking169. The reduction in brain edema from the early phase may 
reduce space-occupying effect and improve regional CBF in the penumbra phase of stroke. 
Here we suggest that rhEPO pretreatment is associated with reduced perivascular edema and a 
protection of the BBB from increased permeability. These effects are probably due to the 
activation of an EPOR-dependent intracellular pathway of the microvascular endothelium, 
which may inhibit transcription factor NF-κB, upregulate expression of tight junction proteins 
and improve abnormalities in the free radical system170,171. Reperfusion phase leads to 
generation of reactive oxygen radicals and lipid peroxidation that are highly noxious to brain 
capillary endothelial cells and its complex tight junctions, which are mostly responsible for 
the integrity of BBB172. EPO has been shown to increase NO synthesis in endothelial cells 
and, under oxidative stress conditions, NO may scavenge ROS173,174. This detoxification also 
prevents membrane lipid peroxidation and consequential additional disruption of BBB in       
I-R170. NF-κB transcriptional activation pathway has been considered a central regulator of 
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 inflammatory response, critical to the regulation of apoptosis, and related to cell adhesion 
molecule expression in endothelial cells175. Liu170 suggested the relation between the 
downregulation of NF-κB with the reversed expression of the tight junction associated 
proteins to be involved in the mechanism of protection of the BBB in I-R rats. We recognize 
some limitations on our study. We speculate rhEPO promotes BBB integrity but we did not 
show direct evidence or quantify BBB permeability changes. Also, it would be interesting to 
perform time course experiments, in particular because long-term effects were not evaluated. 
These dynamics would be of both experimental and clinical relevance. 
 
EPO has been extensively studied in experimental cerebral ischemia, in which population 
target were mainly patients who have suffered from stroke176. Accordingly, the majority of 
work performed focuses on the potential effects of rhEPO after the induction of ischemia 
and/or used permanent cerebral artery occlusion models. Surprisingly, when reviewing the 
literature, only one unpublished study, presented as a poster, evaluated the use of EPO 
administered before induction of transient focal cerebral ischemia177. Data available from this 
trial is very scarce. In here, EPO was administered at a 5.000 IU/Kg dose 2 hours before 
transient MCAO. The results were compared to a saline administered group and authors 
concluded that although EPO did not reduce infarct size at 48 hours, it did improve infarct 
volume 7 days following reperfusion onset, suggesting a neurorestorative action of EPO. The 
technique performed for MCAO and timing of drug administration was not provided. 
Furthermore, the majority of studies usually administer extremely high doses of EPO, over 
5.000 IU/kg, which limits its clinical importance. 
 
Non-erythropoietic tissue-protective EPO variants have been developed, most notably asialo-
EPO (AEPO), nasal formulations of low-sialic acid EPO (NeuroEPO), and carbamylated EPO 
(CEPO) in order to dissociate the erythropoietic effect from the tissue protective effect, and 
thus lessen side effects178. However, rhEPO possesses not only neuron antiapoptotic 
properties but also reduces BBB leakage, enhances blood flow, and promotes angiogenesis 
after brain injury.  It is likely that these non-neuronal effects are not shared by EPO 
derivatives as part of EPO's rescue effects after systemic intravenous delivery in patients. 
Moreover, the clinical safety profile is still under investigation in clinical trials and further 
research is needed before EPO’s variants could be used in patients140. 
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We present first evidence that rhEPO pretreatment at a dose of 1.000 IU/Kg, which has a 
well-described safety profile in humans, reduces brain edema and preserves the penumbra 
functional neuronal pool following in vivo I-R-injury. Considering that a substantial 
proportion of the ischemic lesion could be attributed to mechanical compression induced by 
brain swelling, the development of effective drugs in attenuating the formation and 
progression of brain edema is crucial. Since rhEPO has a higher innate capacity to cross the 
BBB in humans than in rodents179 and given the cerebroprotective effects observed in the 
present study, we believe that clinically available rhEPO could be a potential therapy to 
prevent neuronal injury induced by transient ischemia during neurovascular procedures. 
Further preclinical research is needed to completely understand the underlying mechanisms of 
rhEPO and BBB interactions. However, given the number of animal studies already done on 
cerebral ischemia where rhEPO works well, our investigation may provide supporting 
evidence for a translational clinical trial evaluating single bolus pretreatment of 1.000 IU/kg 
rhEPO in patients undergoing elective transient cerebral artery occlusion during 
cerebrovascular procedures. 
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 5   NEUROPROTECTIVE EFFECTS OF TDZD-8 
 
5.1 Background 	  
Glycogen synthase kinase-3, a cytoplasmic serine/threonine protein kinase, was originally 
described as a component of the metabolic pathway of glycogen metabolism and has been 
involved in a wide range of cellular functions, including glucose metabolism, cytoskeletal 
integrity, gene expression, cell division, and apoptosis180,181. Several studies have implicated 
GSK-3 signaling transduction pathway in multiple central nervous system diseases, 
particularly stroke, traumatic brain injury and neurodegenerative conditions such as 
Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis182,183.  
GSK-3β, one of the two isoforms of GSK-3, is widespread both in developing and adult 
mammalian nervous system and its overexpression induces intrinsic apoptotic signaling 
pathway in neuronal cells following hypoxia/ischemia stimulus184,185. GSK-3β is 
constitutively active in cells, and a wide range of stimuli, including insulin, exerts some of its 
effects by deactivating it. Therefore, GSK-3β is primarily regulated by inhibition by 
numerous kinases, such as Akt, through phosphorylation at Ser9. GSK-3β may be, however, 
regulated by an activation pathway by phosphorylation at Tyr216 as a consequence of a 
proapoptotic stimulus, such as calcium overload.  GSK-3β promotes apoptosis by inhibiting 
prosurvival transcription factors, such as CREB and heat shock factor-1, and facilitating 
proapoptotic transcription factors such as p53186. Moreover, GSK-3β has been shown to 
regulate neuroinflammation by modulating several pro-inflammatory mediators and cell 
autophagy after ischemic brain injury187-189. Additionally, there is growing evidence that 
GSK-3β is implicated in neurodegeneration, in particular in plaque formation and 
neurofibrillary tangle accumulation in Alzheimer disease190. 
 
Lithium is the classical example of a nonspecific GSK-3β inhibitor, which is known to inhibit 
the enzyme in a competitive manner by binding to its magnesium-binding sites, and 
demonstrated to be protective against several neurological insults, including cerebral 
ischemia, suggesting that reduction in activity of GSK-3β improves brain cell survival183. 
Furthermore, topical application of insulin-like growth factor-I (IGF-1), also a non-specific 
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 GSK-3β inhibitor, significantly reduced infarct size after cerebral focal I-R in a rat model191. 
As non-selective inhibitors tend to also inhibit other kinases and may prove to be harmful, the 
acknowledgement of relation between GSK-3β and neuronal apoptosis lead to the 
development of specific antagonists. Martinez described small heterocyclic thiadiazolidinones 
(TDZDs) and their structure-activity relationships as the first non-ATP-competitive selective 
GSK-3β inhibitors192. TDZDs are small molecules with favorable absorption, distribution, 
metabolism, excretion and toxicity properties193. TDZD-8 is a BBB permeable 
compound193,194 and appears to be one the most effective anti-inflammatory and tissue-
protective thiadiazolidinone190 in conditions such as stroke, spinal cord trauma, kidney injury, 
arthritis, or colitis195-199 (Figure 5.1).  
 
Furthermore, phase 2 and phase 3 clinical trials suggest that TDZDs have a favorable safety 
profile and may become clinically available for the treatment of diabetes or some neurological 
diseases in the near future190,200,201. 
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Figure 5.1. Proposed TDZD-8’s neuroprotective effects against cerebral I-R. 
The inhibition of GSK-3β leads to disinhibition of several transcription factors 
such as CREB and HSF-1, and results in induction of major cytoprotective 
proteins such as BDNF, and the well-known antiapoptotic resident of the 
mitochondrial outer membrane Bcl-2. A decrease in GSK-3β activity further 
reduces the activity of pro-apoptotic protein p53 and its downregulating effect 
on Bcl-2. Counteraction of GSK-3 inhibition of VEGF and MMP-9 may enhance 
angiogenesis and neurovascular remodeling as medium/long-term effects. 
Taken together, these effects in reducing apoptosis, decreasing 
neuroinflammation, maintaining BBB integrity, and promoting both neurogenesis 
and angiogenesis may contribute to neuroprotection and functional recovery for 
an I-R insult. Lines with arrows indicate activation and lines with flattened ends 
represent inhibitory effects. Dashed lines represent pathways with possible 
reduced activity as a result of TDZD-8 treatment. BBB, blood-brain barrier; Bcl-
2, B-cell lymphoma 2; BDNF, brain-derived neurotrophic factor; CREB, cAMP 
response element-binding protein; GSK-3β, glycogen synthase kinase-3β; HSF-
1, heat shock factor-1; MMP-9, matrix metallopeptidase 9; PI3K, 
phosphoinositide 3-kinase; VEGF, vascular endothelial growth factor. 
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The aim of this experiment was to investigate the effects of a single dose of TDZD-8 (5 
mg/Kg) as a possible pretreatment against neuronal damage in surgical transient cerebral 
artery occlusion during aneurysmal clipping. TDZD-8 doses were determined in accordance 
with effective previous studies of the central nervous system196,202 and with the established 
therapeutic time window in the clinical setting.  
 
 
5.2 Materials and Methods 
 
A total of 28 adult male Wistar rats (240-340 g) housed under diurnal light conditions with 
unlimited access to food and water were used (n=14 per group). 
 
5.2.1 Intervention 
Animals were randomly assigned to two different groups: TDZD-8 (4-benzyl-2-methyl-1,2,4-
thiadiazolidine-3,5-dione, Sigma-Aldrich, St. Louis, MO, USA) treatment group in which a 
dose of 5 mg/kg 10 minutes previous to ischemia onset was administered in the tail vein IV or 
control group, in which animals administered saline IV. Allocation concealment was attained 
by having drug or saline individually prepared and labeled for each animal according to 
randomization by an independent investigator. The principal investigator, blinded to 
treatment, carried out all surgical procedures. 
 
5.2.2 Surgical Procedure and Outcomes Assessment 
The surgical MCA I-R technique and outcomes assessment methodology at 24-hour 
(neurological examination, quantification of infarct volume and brain edema, determination of 
NSE plasma levels, evaluation of brain tissue by histology, immunohistochemistry and 
western blot techniques) were performed as detailed in the previous chapter (for details, see 
Chapter 4 Section 2). 
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 5.3 Results 
 
All animals lost between 10 to 18% of body weight during the 24-hour recovery period with 
no significant differences between groups. Normothermia was maintained in all animals. 
There were no significant differences between groups with respect to CBF pattern and 
glycemia values during the procedure. 
 
Prophylactic administration of TDZD-8 resulted in significant differences between groups for 
most outcomes and endpoints evaluated. Infarct volume had a 48% reduction in treatment 
group when compared with control group (from 28,02±1,73% to 14,70±1,12%) (Figure 5.2).  
 
 
Figure 5.2. Bar graph comparing total infarct volume between groups. The 
whole brain infarct volume was 265,46±13,88 mm3 for control group and 
125,99±11,26 mm3 for treatment group. Infarct volumes are presented as 
percentages of the total contralateral hemisphere. Data represent the 
mean±SEM (n=8 for each group). ***p<0.001. 
 
Treatment group had a 59% decrease in the ipsilateral hemispheric edema (9,74±1,39% 
compared to 3,99±0,56%) (Figure 5.3).  
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Figure 5.3. Bar graph comparing percentage of hemispheric edema between 
groups. Data represent the mean±SEM (n=8 per group). **p<0.001. 
 
 
TDZD-8 administration prevented the rise of NSE plasma levels (0,20±0,06 ng/ml in 
treatment group compared to 1,88±0,07 ng/ml in control group) (Figure 5.4).  
 
 
Figure 5.4. Bar graph showing NSE plasma levels at 24 hours of reperfusion in 
both control and treatment groups. Data represent the mean±SEM (n=8 for 
control group and n=13 for treatment group). ***p<0.001. 
 
 
Rats treated with TDZD-8 presented significantly less neurological deficits compared to the 
control group (Figure 5.5).  
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Figure 5.5. Scatter plot showing the effects of TDZD-8 at 24 hours on a 9-point 
neurologic score (n=14 per group). Open circles indicate values for individual 
animals. Horizontal bars indicate group median values. TDZD-8 significantly 
reduced neurologic deficits. ***p<0.001, Mann-Whitney test.  
 
 
H&E staining neuropathological examination performed in the ischemic area showed less 
neuropil spongiosis and no perivascular edema on TDZD-8-treated group (Figure 5.6).  
 
67
  
Figure 5.6. Representative photomicrographs H&E brain sections of control and 
TDZD-8-treated rats A, Whole brain section H&E images with delineated infarct 
area of control and TDZD-8-treated rats. B, Representative photomicrographs 
of cerebrovascular changes: neuropil spongiosis (arrows) and perivascular 
edema (Ø) in control animals or its absence in TDZD-8-treated ones (!). Scale 
bar equals 200 µm.  
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 There was a 50% reduction in the number of degenerating Fluoro-Jade positive neurons in 
TDZD-8 treatment group (421,3±45,61 compared to 210,8±16,14 positive cells per section) 
(Figure 5.7).  
 
Figure 5.7. Comparison of degenerating neurons for the two hemispheres in 
both control and TDZD-8-treated groups. A, Representative images of brain 
section stained for degenerating neurons using Fluoro-Jade. Scale bar equals 
20 µm. B, Bar graph comparing the number of positive Fluoro-Jade staining 
neurons per 0.16 µm2 in 4 sections for each rat of the interest area (n=3). Data 
represent the mean±SEM (4 sections from n=3 per group). ***p<0.001. 
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Western blot analysis of p-Akt and total Akt expression was non-significant between groups 
(Figure 5.8) but immunostaining techniques revealed that TDZD-8 significantly increases p-
Akt nucleus translocation (22,7±3,44% of positive p-Akt nuclei in control group compared to 
34,3±3,61% in treatment group) (Figs. 5.9 and 5.10). 
 
 
Figure 5.8. Western Blot showing expression of p-Akt and total Akt with a bar 
graph displaying the densitometric analysis for comparisons of p-Akt/Akt. Data 
represent the mean±SEM (n=3 per group). Results did not show differences 
between groups (p=0.14). 
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Figure 5.9. Akt phosphorylation in control and TDZD-8-treated groups. 
Representative images of the interest area of the I-R injured and contralateral 
hemispheres after double staining for p-Akt and nuclear DAPI. Merged images 
are also presented. Scale bar equals 50 µm.  
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Figure 5.10. Bar graph representing the percentage of positive p-Akt nuclei in 
the interest area for both treatment and control groups, including comparisons 
to contralateral hemispheres. Data represent the mean±SEM (4 sections for 
each n=3 of each group). *p<0.005. 
 
 
5.4  Discussion and Conclusions 
 
To our knowledge, this study provides first evidence that a single TDZD-8 pretreatment dose 
protects rat brain against injury following 60-minute transient MCA ischemia. Our data 
demonstrates that for cerebral I-R injury, TDZD-8: (i) reduced brain damage extent, that is 
48% reduction on the infarct volume and 59% reduction of the hemispheric edema; (ii) 
diminished the number of apoptotic/degenerating neurons; (iii) improved neurological 
performance at 24 hours and (iv) prevented plasma rise of NSE. NSE is assumed to be a 
reliable marker to follow-up neuronal damage since the plasma levels of NSE correlate with 
the extent of cerebral infarction159,160. Blood glucose levels during ischemia or reperfusion 
were not different between groups, indicating that the effects induced by TDZD-8 are 
independent from this variable.  
 
GSK-3β inhibition has been shown to induce neuroprotective effects in cerebral ischemia by 
suppressing neuronal apoptosis and protecting against the loss of barrier integrity due to a 
decrease in the generation of several pro-inflammatory mediators and preventing leukocyte 
adhesion and migration into the brain187,188,195. Furthermore, GSK-3β inhibition is thought to 
promote autophagy activation in ischemic injury, an intracellular catabolic process by which 
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 cells remove their damaged organelles for the maintenance of cellular homeostasis, and to 
induce astrocyte sensitization and tolerance to inflammatory molecules189,203. These 
prosurvival effects for the neurovascular unit are consistent with the histological findings, 
fewer positive degenerating/necrotic neurons stained with Fluro-Jade and lower NSE plasma 
levels seen in the treatment group. GSK-3β inhibition has been proposed to be a potent and 
effective therapeutic approach to attenuating inflammatory response associated with brain 
microvascular endothelial cells dysfunction, which includes preservation of BBB tightness by 
promoting tight junction protein stability188,204. Also, it is possible that TDZD-8 attenuates 
BBB disruption and consequential secondary brain injury.  
 
The PI3K/Akt/GSK-3β pathway is a central mediator in signal transduction pathways that 
help to regulate cell growth, metabolism, inflammation and cell survival162. Akt’s role in cell 
survival was first elucidated by Dudek, who demonstrated that IGF-1 promoted the survival 
of cerebellar cells and that this was mediated by Akt161. Following cerebral ischemia, p-Akt 
levels transiently increase in neurons, and this elevation is believed to be a neuroprotective 
response162,205. Activated protein kinase p-Akt phosphorylates a number of downstream 
cytosolic and nuclear proteins that regulate mitochondrial activity, cell growth, and cell 
survival. The cytosolic modulation include the inhibition of pro-apoptotic molecules such as 
BAD protein, BAX protein, caspases and GSK-3β itself162,194,205. Phosphorylated-Akt has 
been shown to translocate to the nucleus where it phosphorylates several other targets, such as 
p53 tumor suppressor and Forkhead box (FOX) transcription factors, inhibiting their activity 
and ability to induce the expression of death genes206,207. In conclusion, p-Akt is important to 
I-R because its actions may allow cells to escape apoptosis and retain their function.   
 
We found that TDZD-8 did not affect total p-Akt expression in our I-R experiment, which 
may be explained by the fact that GSK-3β inhibition occurs downstream to the 
phosphorylation site of Akt and its potential targets  (Figs. 4.1 and 5.1). Interestingly, an 
increased translocation of p-Akt into the nucleus was observed following TDZD-8 treatment, 
suggesting Akt signaling pathway activation. Accordingly, phosphorylation of Akt appears to 
be essential for its intranuclear permanence206 and recent evidence indicates that Akt plays its 
roles by regulating its phosphorylation state, rather than its protein expression208,209. We 
recognize complete mechanism of action by which TDZD-8 acts in focal cerebral I-R is 
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 lacking and requires further investigation.  
 
The efficacy of intraoperative drugs most commonly used during aneurismal clipping surgery 
offer limited neuroprotection. It has been recently described that thiadiazolidinones 
compounds have potent anti-inflammatory and tissue-protective effects. Our study suggests 
that neuroprotective effects induced by TDZD-8 are likely due to a complex and mixed 
synergic interaction between GSK-3β inhibition and Akt modulation, which acts in the 
neurovascular unit. In conclusion, TDZD-8 is neuroprotective in vivo and may have a role in 
the clinical setting as a pretreatment against neuronal damage induced by transient cerebral 
artery occlusion during cerebrovascular procedures.  
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 6   SUMMARY PROTOCOL FOR CLINICAL TRIAL 
 
Our research supports a translational clinical trial to evaluate use of a single pretreatment dose 
of rhEPO (1.000 IU/kg) in patients undergoing transient cerebral artery occlusion during 
surgical clipping of IA, aiming to evaluate morbidity, volume of brain infarct, extent of brain 
edema, overall survival, quality of life, incidence of vasospasm, and incidence of adverse 
treatment events. Even though higher doses of EPO were shown to promote neuroprotection 
by protecting penumbral cells against apoptosis, we have demonstrated that intravenous 
rhEPO pretreatment at a 1.000 IU/kg dose reduces brain edema and preserves the penumbra 
functional neuronal pool following rodent I-R injury. Moreover, research on translational 
pharmacokinetics showed that rhEPO 1.000 IU/kg per dose IV for neonatal  
encephalopathy149 and for extremely low birth weight infants150 reach drug exposure levels 
that afford optimal neuroprotection in animal models, and concluded this moderate dose is 
likely to minimize risks associated with a higher dose. Also, this dose and route of rhEPO has 
been used in other several clinical trials with no identified additional safety concerns151-153   
Overall, EPO complies the important general clinical rules of a neuroprotective drug: it 
should be safe, readily available, relatively inexpensive, require no special equipment, and 
target mechanisms of injury to improve outcome. EPO is widely available, affordable and has 
proven safe in over two decades of clinical use for erythropoiesis. 
 
A putative clinical trial would be carried out in conformation with the spirit and the letter of 
the Declaration of Helsinki, in accordance with the International Conference on 
Harmonisation (ICH) Good Clinical Practice Guidelines and would require both approvals of 
the National Competent Authority and the author's institutional Review Board. Its registration 
in www.clinicaltrials.gov would be filled thereafter.  
 
A summary protocol is proposed below: 
 
Title 
Eritropoietin as pretreatment for transient cerebral ischemia during aneurysmal surgery: 
multicentre randomized clinical trial of efficacy and safety 
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 Objective and purpose 
To establish the effectiveness and safety of the use of a single pretreatment dose of rhEPO 
(1.000 IU/kg) in patients undergoing surgical clipping of IA that require at least a period of 
transient cerebral artery occlusion. The decision to use temporary clipping would be at the 
discretion of the neurosurgeon. The number of temporary clips applied would be counted 
and the maximal and total time of temporary occlusion recorded. 
 
The following tested hypotheses would be that administration of single pretreatment dose 
of rhEPO (1.000 IU/kg) in patients undergoing transient cerebral artery occlusion during 
surgical clipping of IA would: 1. improve short and long-term clinical course; 2. reduce the 
rate of brain infarct; 3. reduce the rate of brain swelling.  
 
Study Type 
Phase 3 interventional trial 
 
Allocation 
Randomized (web-based electronic platform); 1:1 randomization 
 
Design  
 Endpoint Classification: Efficacy/Safety Study 
 Intervention Model: Parallel Assignment 
 Masking: Double blind (subject, outcomes assessor) 
 Primary Purpose: Treatment 
 Participating Centres: Multicentre 
 
Arms   
Active Arm: Intraoperative intravenous single bolus of 1.000 IU/kg rhEPO administration 
over 30 minutes, at the beginning of surgery and at least 10 minutes before the transient 
occlusion of a cerebral artery during an aneurysmal surgery 
 
Control Arm: No intervention 
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 Primary outcome  1. National Institutes of Health Stroke Score (NIHSS) (Time Frame: baseline, discharge 
date/Day 7, Day 30, Day 90) 	  
 
Key secondary outcome 1. Acute stroke – presence and lesion volume measured by magnetic resonance imaging 
(MRI)210,211 (within 12 to 72 hours post-operative)	  
 
Other secondary outcomes  1. Cerebral edema – presence and lesion volume measured by MRI (within 12 to 72 hours 
post-operative) 	  
2. Modified Ranking Scale (mRS) (time frame: baseline, discharge date/Day 7, Day 30, 
Day 90) 
3. Vasospasm – transcranial Doppler (TCD) according Lindegaard ratio (graded as 
normal, mild and severe; time frame: regularly until postoperative Day 21)  
4. Adverse events related to rhEPO – including deep vein thrombosis, pulmonary 
embolism, seizures, arterial thrombosis such as myocardial infarct/ischemia, 
hypersensitivity reactions, hypertensive crisis.  
5. All-cause mortality (time frame: post-operative day 28) 
 
Types of participants 
Eligibility: >18 years and <70 years 
Gender: Both 
 
Inclusion criteria 
• Age 18-70 years 
• Proposed surgical clipping of a diagnosed IA (regardless rupture, number, location or 
type of aneurysm) 
• Signed informed consent by patient or proxy 
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 Exclusion criteria 
• Hunt and Hess grade 4 or 5 at admission 
• Uncorrected coagulopathy 
• Previous stroke, dementia, severe Parkinson's disease, mental disorders, limb 
dysfunction caused by any diseases or other conditions that may affect therapeutic 
efficacy or functional assessment. 
• Pregnancy  
• Transient cerebral artery occlusion during the surgical procedure was not required 
• Unable to undergo MRI 
• Hemoglobin>15 g/dl before surgery 
• Uncontrolled hypertension 
• Severe coronary, peripheral artery or carotid disease, including recent myocardial 
infarction 
• Chronic renal failure 
• Suspected or known additional disease process that threatens life expectancy (e.g. 
malignancy) 
• Any other condition that in the opinion of the investigator should preclude study 
participation 
 
If sufficient information would be available, the following subgroup analyses could be 
performed: 
1. to determine differences between treatment groups in patients with SAH, i.e. ruptured 
aneurysm 
2. to determine differences between treatment groups in patients with different aneurysm 
locations 
 
Duration of follow-up 
90 days 
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 Estimated enrollment 
Sample size calculations were performed for both primary and key secondary outcomes. 
 
Primary outcome: 2144 patients 
Using a significance of p=0.05 and a power of 80% (ability to detect a difference between 
groups), assuming an overall rate of symptomatic stroke due to transient clipping of 
17%30,31 and an effect size of 25%, that is, assuming that rhEPO therapeutic effect 
decreases this outcome to 13%, a minimum of 1072 patients per group will be needed 
before the final analysis.  
 
Key secondary outcome: 702 patients 
Using a significance of p=0.05 and a power of 80%, assuming an overall rate of the 
primary outcome ‘stroke’ of 40%30,31,33,34, and an effect size of 25%, that is, assuming that 
rhEPO therapeutic effect decreases this outcome to 30%, a minimum of 702 patients will 
be needed before the final analysis.  
 
Planned interim analyses with sample size re-assessments will be performed every 70 
patients. For instance, if treatment had an effect size of 50%, that is, rhEPO therapeutic 
effect decreases rate of primary outcome from 17% to 8.5%, a total of 476 patients would 
be enough to demonstrate treatment effect. 
 
 
Timeline 
5 years 
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 7   FINAL COMMENTS 
 
Surgical or endovascular interventions are the options for treatment of IAs. As endovascular 
techniques gain popularity, the aneurysms that are being sent for clipping are fewer and more 
complex. Therefore, surgical aneurysms are increasingly challenging for microvascular 
neurosurgeons. Temporary clip applications will remain essential. 
 
Any strategy to reduce intraoperative risks to minimum is critical, which may include 
intraoperative physiological monitoring, vascular clips design or cerebroprotective drugs. 
Research is still looking for an effective neuroprotective drug that may be used in daily 
practice. The translational disappointments have created a great deal of pessimism regarding 
the future of neuroprotection trials in humans. However, the smaller number of neurosurgical 
patients requiring temporary clipping are being disregarded by the large number of patients 
with spontaneous stroke. Neurosurgical patients could benefit from best timing/route for drug 
administration and from strict physiological variables control, raising chances of clinical 
success. The concerns on differences between animal and human studies may explain why 
most preclinical trials evaluating neuroprotective agents have been using either permanent 
cerebral ischemia models or treatment drug administration after the onset of ischemia, as the 
clinical world would require in patients with ongoing stroke. This research was designed for 
the assessment of drugs that could be used against cerebral injury due to intraoperative 
transient ischemia. Experimental planning, animal model and drug selection, as well as 
effective dose selection, considering dose-limiting toxicity in humans, route of administration, 
and time-window to treatment were major concerns to approach the clinical problem. 
 
There is a multiplicity of mechanisms causing brain injury following cerebral I-R. In this 
study, we evaluated neuroprotective compounds with a possible multimodal mode of action. 
This concept considers the use of agents with potential recovery-enhancing properties besides 
its possible neuroprotective effects. We have studied a promising drug with well-known anti-
inflammatory actions, TDZD-8, on a MCA I-R rodent model, with very encouraging results. 
Phase 3 clinical trials for marketing approval of this molecule are still ongoing, which limits 
its clinical use. Furthermore, we present the first study based on the same animal model to 
evaluate potential benefits of a single moderate dose of intravenous rhEPO, suitable for 
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 translation to humans, administered prior the ischemia onset. Even though higher doses of 
EPO were shown to promote neuroprotection by protecting penumbral cells against apoptosis, 
our results demonstrate that 1.000 IU/kg rhEPO pretreatment dose may also attenuate cerebral 
I-R injury. Contrary to what one would expect, results suggest that protective outcome of 
rhEPO is more a result of an indirect effect in brain edema due to BBB preservation rather 
than direct neuronal antiapoptotic actions. These effects are in line with the emerging concept 
of neurovascular unit protection, which emphasizes that all cell types in the brain, including 
neurons, glial and vascular elements, must be considered for rescue and preservation. Since 
rhEPO is widely available, affordable, and with a well-known safety profile in humans, a 
translational clinical trial evaluating single bolus pretreatment dose of 1.000 UI/kg in patients 
undergoing elective transient cerebral artery occlusion during aneurysm surgery was planned. 
 
The writing of this thesis allowed my introduction into animal research.  It was interesting to 
realize that, as with real life surgery, small pitfalls can lead to unpleasant events. The most 
difficult step in accomplishing this work was, by far, setting up and establishing the animal 
model. Therefore, this work was not meant to end here. It is reassuring that methodology is 
being further improved and other experiments are being planned.  
 
Nevertheless, it will be very gratifying once this thesis results in a clinical trial in a nearby 
future.  
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TransienT vessel occlusion may be unavoidable dur-ing neurosurgical or endovascular procedures and might lead to brain damage. Unlike in stroke pa- tients, to which most cerebral ischemia animal studies re-fer,19,28 in patients undergoing neurovascular procedures the onset of temporary artery occlusion can be planned 
in advance, allowing the best timing for preventive ma-
neuvers or neuroprotective drug administration to be per-
formed, even before the onset of ischemia.
The risk of brain infarction with temporary artery 
occlusion in patients undergoing clip ligation for cerebral 
aneurysm has been reported to be as high as 45%.16 Brain 
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Object. There is an unmet clinical need to develop neuroprotective agents for neurosurgical and endovascular 
procedures that require transient cerebral artery occlusion. The aim in this study was to explore the effects of a single 
dose of recombinant human erythropoietin (rhEPO) before middle cerebral artery (MCA) occlusion in a focal cere-
bral ischemia/reperfusion model.
Methods. Twenty-eight adult male Wistar rats were subjected to right MCA occlusion via the intraluminal thread 
technique for 60 minutes under continuous cortical perfusion monitoring by laser Doppler flowmetry. Rats were di-
vided into 2 groups: control and treatment. In the treated group, rhEPO (1000 IU/kg intravenously) was administered 
10 minutes before the onset of the MCA ischemia. At 24-hour reperfusion, animals were examined for neurological 
deficits, blood samples were collected, and animals were killed. The following parameters were evaluated: brain 
infarct volume, ipsilateral hemispheric edema, neuron-specific enolase plasma levels, parenchyma histological fea-
tures (H & E staining), Fluoro-Jade–positive neurons, p-Akt and total Akt expression by Western blot analysis, and 
p-Akt–positive nuclei by immunohistochemical investigation.
Results. Infarct volume and Fluoro-Jade staining of degenerating neurons in the infarct area did not vary be-
tween groups. The severity of neurological deficit (p < 0.001), amount of brain edema (78% reduction in treatment 
group, p < 0.001), and neuron-specific enolase plasma levels (p < 0.001) were reduced in the treatment group. Peri-
vascular edema was histologically less marked in the treatment group. No variations in the expression or localization 
of p-Akt were seen.
Conclusions. Administration of rhEPO before the onset of 60-minute transient MCA ischemia protected the brain 
from this insult. It is unlikely that rhEPO pretreatment leads to direct neuronal antiapoptotic effects, as supported by the 
lack of Akt activation, and its benefits are most probably related to an indirect effect on brain edema as a consequence 
of blood-brain barrier preservation. Although research on EPO derivatives is increasing, rhEPO acts through distinct 
neuroprotective pathways and its clinical safety profile is well known. Clinically available rhEPO is a potential therapy 
for prevention of neuronal injury induced by transitory artery occlusion during neurovascular procedures.
(http://thejns.org/doi/abs/10.3171/2014.2.JNS132197
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recombinant human EPO. 
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tolerance to reperfusion injury depends on several fea-
tures, such as the degree, size, location, and duration of 
the ischemia; presence of subarachnoid blood; timing of 
surgery; patient’s age; body temperature; genetic factors; 
and other comorbidities. Reperfusion injury is attributed 
to numerous events, including inflammatory response, 
oxidative stress, loss of blood-brain barrier (BBB) integ-
rity, cerebral edema, and hemorrhagic transformation.22 
Particularly, focal ischemia followed by reperfusion leads 
to severe damage to the BBB integrity, allowing water 
and macromolecules to cross into brain tissue as early as 
20–45 minutes following permanent middle cerebral ar-
tery (MCA) occlusion.15 The detrimental edema further 
reduces focal blood flow, and induces cell necrosis and 
apoptosis.37 Furthermore, widespread interactions among 
BBB disruption, edema formation, and lower blood flow 
become a vicious cycle, which accelerates brain damage.
Erythropoietin (EPO), a 30.4-kD glycoprotein, is 
a natural hormone originally identified for its role in 
erythropoiesis and successfully used for anemia treat-
ment in the last 2 decades. The finding that EPO and its 
receptor (EPOR) are expressed throughout the brain in 
glial cells, neurons, and endothelial cells suggested that 
EPO could have hematopoiesis-independent effects on 
the nervous system.18,27 Endogenously produced EPO 
and/or expression of EPOR gives rise to autocrine and 
paracrine signaling in different organs, particularly dur-
ing hypoxia, toxicity, and injury conditions. In the brain, 
EPO mRNA levels have been shown to remain elevated 
for more than 24 hours during the duration of the hypoxic 
stimuli.8 Accordingly, following ischemic/hypoxic injury, 
dramatic changes have been reported in the expression 
of EPO and EPOR within and around infarcts in human 
brain regions.36 Erythropoietin has been shown to regu-
late a variety of cell functions such as ionic balance, neu-
rotransmitter synthesis, and cell survival.40,41 Research 
has also shown that a high dose of systemically adminis-
tered recombinant human EPO (rhEPO) crosses the BBB, 
leading to neuroprotective and neurotrophic effects.5,7 As 
a result, several trials are currently ongoing to identify 
possible benefits in the usage of rhEPO for specific clini-
cal situations requiring neuroprotection (http://clinical 
trials.gov/show/NCT01732146; http://clinicaltrials.gov/
show/NCT00513240; http://clinicaltrials.gov/show/NCT 
01378273).
To our knowledge, we present the first animal study 
based on an MCA ischemia/reperfusion (I/R) model aim-
ing to investigate the potential benefits of a single dose 
of 1000 IU/kg intravenous rhEPO as a possible pretreat-
ment against neuronal damage in neurovascular proce-
dures that require transient cerebral artery occlusion. The 
selected dose and route has been used in several clinical 
trials with no identified additional safety concerns, and 
thus could be safely translated to the clinical setting.9,13,29
Methods
A total of 28 adult male Wistar rats weighing between 
240 and 340 g and housed under diurnal light conditions 
with unlimited access to food and water were used (14 per 
group). Animal care followed the recommendations of 
the European Convention for the Protection of Vertebrate 
Animals Used for Experimental and Other Scientific Pur-
poses (Council Directive 86/609/EEC) and National Law 
1005/92 (rules for protection of experimental animals). 
The Institutional Animal Care and Use Committee ap-
proved all animal procedures. All efforts were made to 
minimize animal suffering and to reduce the number of 
animals used.
Erythropoietin Administration
A dose of 1000 IU/kg rhEPO (epoietin b, Hoffmann-
La Roche) was administered intravenously in the tail vein 
10 minutes before the onset of ischemia. The control group 
had the same volume of saline administered similarly.
Middle Cerebral Artery Ischemia-Reperfusion
Food was withheld from rats 12 hours prior to sur-
gery. Anesthesia was induced by intraperitoneal adminis-
tration of a ketamine (80 mg/kg) and xylazine (8 mg/kg) 
mixture, supplemented as needed. Anesthetized rats were 
placed on a thermostatically controlled heating pad, a rec-
tal probe was inserted, and body temperature was moni-
tored and maintained between 36.5°C and 37.5°C. Tran-
sient focal cerebral ischemia was induced by 60-minute 
right MCA occlusion followed by 24-hour reperfusion, as 
reported.24 Briefly, under the operating microscope, the 
right common carotid artery (CCA), internal carotid ar-
tery (ICA), and external carotid artery (ECA) were ex-
posed and isolated from branches through a midline neck 
incision. The ECA was tied and cut at approximately 5 
mm from the bifurcation and a loose 6-0 silk knot was 
placed around the ECA origin. Afterward, microvascular 
clips were placed on the CCA and ICA, an ECA stump 
arteriotomy distal to the loose knot was performed, and 
a 4-0 nylon silicone monofilament with a rubber-coated 
tip (Doccol Corp.) was inserted. The suture that had been 
placed around the ECA stump and intraluminal nylon 
filament was tightened to prevent bleeding and the clips 
were removed. The filament was then gently introduced 
(19–21 mm) into the ICA to the level where the MCA 
branches out, until the laser Doppler signal decreased to 
less than 30% of baseline, occluding the right MCA at its 
origin at the circle of Willis. After a 60-minute period of 
ischemia the thread was cautiously removed, reestablish-
ing the blood flow in the MCA. The ECA was perma-
nently ligated at the level of bifurcation. Animals were al-
lowed to recover and then were killed with an anesthetic 
overdose at 24 hours into reperfusion.
Blood Flow Measurements
Cortical cerebral blood flow (CBF) was monitored by 
laser Doppler flowmetry (PeriFlux 4000 System, Probe 
407; Perimed Instruments) in the supply territory of the 
right MCA where transient ischemia was to be induced; 
CBF was measured before, during occlusion, and within 
1 hour of reperfusion. A small bur hole was drilled 2 mm 
posterior to the bregma and 3.5 mm lateral to the mid-
line, and the micro-Doppler probe was positioned above 
the dura mater in a holder glued to the bone. Steady-state 
baseline values were recorded before occlusion, and the 
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CBF measured during occlusion and reperfusion was ex-
pressed as a percentage of the baseline values. Rats with 
CBF patterns suggesting subarachnoid hemorrhage, in-
complete ischemia (CBF did not decrease to a maximum 
of 30% of baseline), or incomplete reperfusion (CBF did 
not recover to more than 80% of baseline within 30 min-
utes of filament withdrawal) were excluded and replaced.
Neurological Examination
At 24 hours, a 9-point-scale neurological test (0 = 
normal to 9 = highest handicap) was performed in the 
rats, as previously described.20 Four tests were performed 
by an observer who was blinded to the treatment groups 
to assess the following: 1) spontaneous activity (moving/
exploring = 0, moving without exploration = 1, no dis-
placement = 2); 2) laterality in movement (symmetrical = 
0, left drifting when elevated by the tail = 1, spontaneous 
left drifting = 2, circling to the left without displacement 
or spinning = 3); 3) resistance to left forepaw stretching 
(no stretching allowed = 0, stretching allowed = 1, no re-
sistance = 2); and 4) parachute reflex (symmetrical = 0, 
asymmetrical = 1, contralateral forelimb retracted = 2). 
Scores for each test were added to obtain the final neuro-
logical score.
Infarct Volume and Brain Edema Assessment
The brains were removed, placed in a brain matrix 
(World Precision Instrument), and sliced in 2-mm-thick 
coronal sections, beginning 2 mm from the frontal pole 
and ending rostral to the corticocerebellar junction, re-
sulting in 6 slices per animal (8 rats per group). The 
sections were stained in 2% 2,3,5-triphenyltetrazolium 
chloride (Sigma-Aldrich) saline solution for 10 minutes 
at 37°C in the dark and fixed in 4% paraformaldehyde 
at 4°C overnight. Sections were scanned and analyzed 
using ImageJ software (version 1.45). Brain infarction 
was visualized as areas of unstained (white) tissue, which 
contrasted from brick-red–stained areas of viable tissue. 
Summing the infarct area of each coronal slice and mul-
tiplying that number by the thickness of the sections al-
lowed the calculation of the total infarct volume. Right 
and left hemisphere volumes were calculated similarly. 
The amount of infarction was expressed in absolute terms 
in cubic millimeters and as a percentage of the infarct 
volume in the whole forebrain, adjusted for brain ede-
ma.38 An index of brain edema was assessed by calculat-
ing the percent increase of size of the ipsilateral (injured) 
hemisphere compared with the contralateral (uninjured) 
hemisphere. A single observer blinded to the individual 
treatment performed the analysis described.
Determination of Neuron-Specific Enolase Plasma Levels
Blood samples were taken by puncture of the left car-
diac ventricle prior to killing. Blood was centrifuged at 
10,000 rpm for 10 minutes and the isolated serum was 
frozen and stored until time of assay. Serum neuron-spe-
cific enolase (NSE) measurements were performed with 
an electrochemiluminescence immunoassay by using a 
sandwich technique with double monoclonal antibodies 
directed against NSE and an Elecsys 2010 analyzer (anti-
bodies and apparatus both from Roche Diagnostics). Data 
were normalized to nanograms per milliliter of plasma.
Histological and Immunohistochemical Procedures
Rat brains were removed, fixed in 4% paraformal-
dehyde in phosphate-buffered saline (PBS) for 72 hours 
at room temperature, dehydrated through a graded etha-
nol series, and embedded in paraffin (3 per group). Then, 
H & E staining was performed as previously described11 
and images were acquired using a bright-field microscope 
(Axioskop, Zeiss).
For Fluoro-Jade staining, 6-μm-thick coronal sec-
tions were deparaffinized and rehydrated. Slides were 
first immersed in 100% alcohol for 3 minutes, followed 
by 1 minute in 70% alcohol and 1 minute in distilled wa-
ter. The slides were then transferred to a solution of 0.06% 
potassium permanganate for 15 minutes on a shaker table 
and protected from light. After that the slides were rinsed 
in distilled water for 1 minute and immersed in Fluoro-
Jade B (Chemicon) staining solution 0.001% for 30 min-
utes with moderate agitation. Slides were rinsed for 1 
minute in each of 3 distilled water washes and dried at 
room temperature. The dry slides were cleared by immer-
sion in xylene for at least 1 minute before coverslipping 
with DPX (Fluka or Sigma-Aldrich. The tissue was then 
examined using an epifluorescent microscope (Axios-
kop, Zeiss) with blue (450–490 nm) excitation light. The 
number of positive Fluoro-Jade B–positive neurons was 
counted in 4 sections of 0.16 mm2 (3 per group) within the 
region of interest by using ImageJ software version 1.45 
and the total was expressed as positive cells/section.
For immunostaining, 6-mm-thick coronal sections 
were submitted to antigen retrieval in 20 mM citrate buf-
fer with 1.5% H2O2 for 15 minutes at room temperature in the dark, incubated for 10 minutes in Tris/EDTA buffer at 
84°C, and blocked for 1 hour at room temperature in 1% 
bovine serum albumin (BSA) in PBS. Primary antibody, 
rabbit anti–p-Akt (1:100, Cell Signaling Technology) was 
used in 0.5% BSA in PBS overnight at 4°C. After wash-
ing in PBS, sections were incubated for 1 hour at room 
temperature with anti–rabbit antibodies coupled to Al-
exaFluor 568 (#A11077, 1:1000; Invitrogen) in 0.5% BSA 
in PBS, incubated for 20 minutes in DAPI, and mounted 
with Shandon Immu-Mount Aqueous Nonfluorescing 
Mounting Medium (Thermo Scientific). Tissue sections 
were visualized with an epifluorescent microscope (Ax-
ioskop, Zeiss), and the total number of nuclei (those with 
DAPI staining) and those positive for p-Akt were counted 
to present the results as percentage of p-Akt–positive nu-
clei (2 sections within the region of interest; 3 per group).
Western Blot Analysis
For Western blot analysis (3 per group), cells from 
frozen tissue samples were lysed in RIPA (radioimmu-
noprecipitation assay) buffer containing Tris 50 mM (pH 
8.0), 5 mM EDTA (pH 8.0), 150 mM NaCl, 1% NP-40, 
10% glycerol, and 0.1% sodium dodecyl sulfate, and 
sonicated for 20 seconds. The lysate was centrifuged at 
14,000 g for 10 minutes at 4°C and the supernatants were 
collected and stored at -80°C. Protein concentrations 
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were determined using Nanodrop ND-1000. Cell extracts 
containing equal amounts of protein (100–150 μg) were 
separated on sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis and transferred to a nitrocellulose mem-
brane. The membranes were blocked with 5% nonfat 
milk, incubated with the primary antibodies overnight at 
4°C (anti–rabbit p-Akt [1:1000, #12178; Cell Signaling], 
and anti–rabbit Akt [1:1000, #4691; Cell Signaling]), and 
then with a horseradish peroxidase-labeled secondary an-
tibody for 1 hour at room temperature. After extensive 
washes, immunoreactive bands were detected by Lumi-
GLO (Cell Signaling) and visualized by autoradiography 
with Hyperfilm ECL. Phosphorylation levels of Akt were 
analyzed by the ratio of p-Akt to total Akt levels and ex-
pressed as “-fold” change.
Statistical Analysis
Statistical analysis was performed using Graph-
Pad Prism software, version 6.0. Parametric data were 
analyzed using the Student t-test for single comparisons 
between groups, and nonparametric data (neurological 
scores) were subjected to the 2-tailed Mann-Whitney test. 
Data are presented as the mean ± SEM for “n” observa-
tions, where “n” represents the number of animals stud-
ied. For histological scoring and Western blot analysis, 
each data point represents analyses of brain sections ob-
tained in 3 individual rats. A p value of ≤ 0.05 was the 
threshold for a statistically significant difference or as-
sociation.
Results
All animals lost between 10% and 18% of body 
weight during the 24-hour recovery period, with no sig-
nificant differences between groups. Normothermia was 
maintained in all animals. There were no significant dif-
ferences between groups with respect to CBF pattern and 
glycemia values during the procedure.
Results showed no difference between groups in the 
infarct volume. The total brain infarct volume was 265.46 
± 13.88 mm3 for the control group and 223.33 ± 12.97 
mm3 for the treatment group. Expressed as a percentage,38 
infarct volume was 28.02% ± 1.73% in the control group 
and 25.71% ± 1.41% in the rhEPO group (Fig. 1). Also, the 
number of positive Fluoro-Jade degenerating neurons in 
the area of interest was similar between groups (Fig. 2). 
Brain swelling index was significantly decreased in the 
treatment group when compared with the control group 
(2.11% ± 0.46% and 9.74% ± 1.39%, respectively; p < 
0.001) (Fig. 3). Accordingly, histological analysis of the 
brain parenchyma (with H & E staining) revealed neu-
ropil spongiosis and perivascular edema, which was less 
marked in the rhEPO-treated group (Fig. 4). The treat-
ment group had significantly lower NSE plasma levels 
compared with the control group (1.17 ± 0.07 ng/ml com-
pared with 1.88 ± 0.07 ng/ml; p < 0.001) (Fig. 5). This was 
a relevant parameter for assessing the prognosis of ce-
rebral hypoxia-ischemia, and presented significantly re-
duced neurological deficits (p < 0.001) (Fig. 6). Although 
it is believed that EPO activates Akt, no differences were 
found between groups for the p-Akt/Akt ratio in Western 
blot analysis (Fig. 7) and for percentage of p-Akt–positive 
nuclei in immunohistochemical studies (data not shown).
Discussion
Our study reveals that rhEPO exerts protective ef-
fects in focal cerebral I/R. This is in line with the tissue-
protective effects of rhEPO described in several animal 
models of I/R injury, as demonstrated by our research 
group.25,30 Recombinant human EPO has been consistent-
Fig. 1. Bar graph comparing total infarct volume between control 
and rhEPO-treated groups. Infarct volumes are presented as percent-
ages of the total volume of forebrain. Data represent the mean ± SEM 
(8 per group). Differences between groups were not significant.
Fig. 2. Bar graph comparing the number of positive Fluoro-Jade 
neurons in the area of interest in the ipsilateral and contralateral hemi-
spheres. Data represent the mean ± SEM (4 × 0.16–mm2 sections for 
each specimen; 3 per group). Values were not significant. 
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ly tested at high doses (> 5000 IU/kg) in rodent models of 
permanent cerebral artery occlusion, and has been shown 
to be more effective when administered within 6 hours 
after stroke onset.28 We investigated the effects of a single 
lower dose of rhEPO as a pretreatment (1000 IU/kg) in an 
I/R rodent model. The dose used has been safely tested in 
humans.9,13,29 Our results suggest that intravenous admin-
istration of a single 1000-IU/kg dose of rhEPO just prior 
to a transitory occlusion of a cerebral artery may decrease 
secondary brain insult, resulting in a better neurological 
outcome.
Regarding infarct volume outcome, we found no dif-
ferences between groups at 24-hour reperfusion, although 
the improved neurological status and significantly lower 
NSE plasma levels observed at that point could indicate 
that this outcome may change over time between groups. 
Because NSE is an enzyme that is rapidly released by in-
jured neurons, lower NSE plasma levels in the treatment 
group may suggest a smaller penumbra area and a better 
clinical outcome. Plasma levels reach their maximum at 
24 hours, and the best correlation between infarct size and 
plasma levels occurs at Day 3.14 Plasma levels of this ki-
nase have been found to be increased even before the on-
set of clinical symptoms, and are strongly correlated with 
the clinical score and histological damage when clinical 
symptoms are present.14 The NSE plasma levels probably 
reflect neuronal cell death, suggesting that NSE is a reliable 
marker when used to follow neuronal damage.1
There is evidence that EPO treatment activates the 
antiapoptotic molecule Akt.31,32 On phosphorylation, the 
serine-threonine kinase Akt promotes cell survival by 
inactivating several targets, including cell-death antago-
nist BCL-2, glycogen synthase kinase–3b (GSK-3b), and 
caspase-9, or else it activates prosurvival molecules,33 
suggesting that the phosphatidylinositol 3–kinase (PI3K)/
Fig. 3. Bar graph depicting the percentage of hemispheric edema 
in both control and rhEPO-treated groups. Data represent the mean ± 
SEM (8 per group). Values were significant, representing a 78% reduc-
tion of ipsilateral hemispheric edema in the treatment group compared 
with control group. ***p < 0.001.
Fig. 4. Representative photomicrographs of brain sections obtained in control and rhEPO-treated rats. A: Whole-brain-
section images with delineated infarct areas. B: Cerebrovascular changes in the infarct area: neuropil spongiosis (arrows) and 
perivascular edema (black-and-white arrowhead) in control animals or its absence (black arrowhead) in rhEPO-treated ones. 
Contralateral hemispheres had no relevant changes. H & E. Bar = 200 mm.
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Akt/GSK-3b pathway is involved in the neuroprotective 
effect of rhEPO.31 Phosphorylation of Akt is coupled to 
its nuclear translocation where it phosphorylates nuclear 
targets, suppressing the transcription of death genes.6 Un-
expectedly, our results did not show an increase in the 
expression of p-Akt/Akt (Western blot) or a p-Akt nuclear 
translocation (immunohistochemistry). The lack of PI3K/
Akt/GSK-3b pathway activation could be explained by the 
use of lower rhEPO doses in our study when compared 
with previous ones.19,28 In fact, only up to 1% of systemi-
cally administered rhEPO crosses the BBB in primates,21 
and poor penetration into the BBB is expected even when 
administering up to 10,000 IU/kg intravenously as single 
doses.12 This poor crossing ratio suggests that high doses 
of systemically administered rhEPO are needed for direct 
neuron-protective purposes. 
On the other hand, Xiong et al.43 have previously 
demonstrated that EPO significantly provides neuropro-
tection following traumatic brain injury in EPOR-null 
mice; that is, even in the absence of EPOR in the neu-
ral cells, probably mediated through vascular protection. 
We postulate that the benefits observed in prophylactic 
rhEPO administration were not due to a direct neuronal 
action in the infarct area but were the result of an indirect 
effect on brain swelling as a consequence of diminished 
BBB disruption. This is also in line with the histologi-
cal findings and lack of difference between treatment and 
control groups in the number of positive Fluoro-Jade cells 
that label degenerating neurons.
Fig. 7. Western blot showing expression of p-Akt and total Akt, with a 
bar graph showing the densitometric analysis of the relative intensity of 
p-Akt, normalized against total Akt. Data represent the mean ± SEM (3 
per group). Results did not show differences between groups.
Fig. 6. Scatterplot showing the effects of rhEPO at 24 hours on a 
9-point neurological scale (14 per group). Open circles indicate values 
for individual animals. Horizontal bars indicate group median values. 
The rhEPO significantly reduced neurological deficits. ***p < 0.001, 
Mann-Whitney test.
Fig. 5. Bar graph showing a 38% reduction of NSE plasma levels 
at 24 hours of reperfusion in the rhEPO-treated group. Data represent 
the mean ± SEM (n = 8 for control and 13 for treatment group). ****p 
< 0.001.
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Cerebral edema is a well-recognized factor for high 
morbidity and mortality in large-territory ischemic 
strokes.42 Brain edema following MCA occlusion has 
been shown to increase gradually over the first 48 hours 
before peaking.34 The reduction in brain edema from the 
early phase may reduce the space-occupying effect and 
improve regional CBF in the penumbra phase of stroke. 
Here we suggest that rhEPO pretreatment is associated 
with reduced perivascular edema and with protection 
of the BBB from increased permeability. These effects 
are probably due to activation of an EPOR-dependent 
intracellular pathway of the microvascular endothelium, 
which may inhibit the transcription factor nuclear factor–
kappa B (NF-kB), upregulate expression of tight-junction 
proteins, and improve abnormalities in the free-radical 
system.23,26 
The reperfusion phase leads to generation of reac-
tive oxygen radicals and lipid peroxidation that are highly 
noxious to the brain’s capillary endothelial cells and its 
complex tight junctions, which are mostly responsible 
for the integrity of the BBB.2,4 Erythropoietin has been 
shown to increase nitric oxide synthesis in endothelial 
cells and, under oxidative stress conditions, nitric oxide 
may scavenge reactive oxygen species.3,39 This detoxi-
fication also prevents membrane lipid peroxidation and 
consequential additional disruption of the BBB in I/R.2 
The NF-kB transcriptional activation pathway has been 
considered a central regulator of inflammatory response, 
critical to the regulation of apoptosis, and related to cell 
adhesion molecule expression in endothelial cells.17 Liu et 
al.23 suggested that the relation between the downregula-
tion of NF-kB and the reversed expression of the tight 
junction–associated proteins is involved in the mecha-
nism of protection of the BBB in rats with I/R injury.
 We recognize some limitations on our study. We 
speculate that rhEPO promotes BBB integrity but we did 
not show direct evidence or quantify BBB permeability 
changes. Also, it would be interesting to perform time 
course experiments. These dynamics would be of both 
experimental and clinical relevance.
Nonerythropoietic tissue-protective EPO variants 
have been developed, most notably asialo-EPO (AEPO), 
intranasal formulations of low-sialic-acid EPO (Neuro-
EPO), and carbamylated EPO (CEPO) to dissociate the 
erythropoietic effect from the tissue-protective effect, 
and thus lessen side effects.36 However, rhEPO possesses 
not only neuron antiapoptotic properties but also reduces 
BBB leakage, enhances blood flow, and promotes angio-
genesis after brain injury. It is likely that these nonneu-
ronal effects are not shared by EPO derivatives as part of 
EPO’s rescue effects after systemic intravenous delivery 
in patients. Moreover, the clinical safety profile is still un-
der investigation in clinical trials and further research is 
needed before EPO variants could be used in patients.40
Conclusions
We present the first evidence that rhEPO pretreat-
ment at a dose of 1000 IU/kg, which has its safety profile 
in humans well described, reduces brain edema and pre-
serves the penumbra functional neuronal pool following 
in vivo I/R injury. Considering that a substantial propor-
tion of the ischemic lesion could be attributed to mechan-
ical compression induced by brain swelling, the develop-
ment of effective drugs to attenuate the formation and 
progression of brain edema is crucial. Because rhEPO 
has a higher innate capacity to cross the BBB in humans 
than in rodents,10 and given the neuroprotective effects 
observed in the present study, we believe that clinically 
available rhEPO could be a potential therapy to prevent 
neuronal injury induced by transient ischemia during 
neurovascular procedures. Further research is needed 
to completely understand the underlying mechanisms of 
rhEPO and BBB interactions. A translational clinical trial 
could be supported.
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a  b  s  t  r  a  c  t
There  is  an unmet  clinical  need  to develop  neuroprotective  agents  for  cerebrovascular  procedures  requir-
ing  transient  cerebral  artery  occlusion.  This  study  aims  to  investigate  the  effects  of a  single  pre-treatment
dose  of  4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione  (TDZD-8),  a glycogen  synthase  kinase-3
(GSK-3)  inhibitor,  in  a  transient  focal  cerebral  ischemia  model.  Twenty-eight  male  adult  Wistar  rats  were
subjected  to right  middle  cerebral  artery  (MCA)  occlusion  via intraluminal  thread  technique  for  60  min
under  continuously  cortical  perfusion  monitoring  by  laser-Doppler  ﬂowmetry.  Rats  were  divided  into  two
groups:  control  or  treatment  groups.  In the  treated  group,  TDZD-8  (5 mg/kg;  intravenously)  was  admin-
istered  10  min before  the onset  of  the  MCA  ischemia.  At  24-h  reperfusion,  the  following  parameters  were
evaluated:  neurological  deﬁcits,  brain  infarct  volume,  ipsilateral  hemispheric  oedema,  neuron  speciﬁc
enolase  (NSE)  plasma  levels,  parenchyma  histology  (H–E staining),  Fluoro-Jade  positive  neurons,  p-Akt
and  total  Akt  expression  by  western  blot  analysis  and  p-Akt-positive  nuclei  by immunohistochemistry.
Infarct  volume  (P < 0.001)  and  neurological  deﬁcits  severity  (P  < 0.001)  were  reduced in TDZD-8  treated
group.  TDZD-8  attenuated  hemispheric  oedema  (P <  0.001),  prevented  the  NSE plasma  level  increase
(P  <  0.001)  and diminished  the  number  of  degenerated  neurons  in the  infarct  area  (P < 0.001),  as  shown
by  Fluoro-Jade  staining.  TDZD-8  treated  rats  showed  few  signs  of  perivascular  oedema  when  compared
to  control  group.  No  variations  in  total  Akt and  p-Akt expression  were  observed;  instead  immunohis-
tochemistry  showed  increased  p-Akt  nucleus  translocation  in  TDZD-8  treated  rats  (P  <  0.05).  TDZD-8  is
a  potential  pre-treatment  intraoperative  drug  to prevent  neuronal  injury  induced  by transitory  artery
occlusion  during  cerebrovascular  procedures.. Introduction
The use of elective transient artery occlusion in intracranial
neurysm surgery is widely accepted and it is sometimes an
ssential approach to decrease the risk of intraoperative rupture,
acilitate safer dissection of the aneurysm neck and perforators,
Abbreviations: BBB, Blood-brain barrier; CBF, Cerebral blood ﬂow; CCA, Com-
on carotid artery; ECA, External carotid artery; GSK, Glycogen synthase kinase;
–E,  Hematoxilin–Eosin; ICA, Internal carotid artery; MCA, Middle cerebral artery;
SE, Neuron speciﬁc enolase; TDZD-8, 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-
,5-dione, thiadiazolidinone-8; TTC, Triphenyltetrazolium chloride.
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allow precise clip placement, and open the aneurysm for thrombus
or atheroma removal. Generally, it is recommended to limit the
duration of temporary occlusion to brief periods, restricting to less
than 10 min  to avoid ischemic damage and neurologic complica-
tions [1,2]. Still, up to 45% of patients undergoing clipping surgery
with transient vessel occlusion experience brain infarct [2].
Brain  ischemia leads to cell mitochondrial dysfunction that
result in a rapid loss of high-energy phosphate compounds and
generalized cell depolarization. Nevertheless, when ischemia is
induced for a short period of time, the recovery of energy
metabolism during reperfusion can restore ionic imbalance. Reper-
fusion itself may, however, lead to brain damage due to numerous
events, including inﬂammatory response, oxidative stress, blood-
brain barrier (BBB) disruption, cerebral oedema and haemorrhagic
transformation. The paradox of reperfusion injury can be under-
stood in terms of counter-adaptive changes occurring during
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erebral ischemia that predispose the tissues to cellular dys-
unction, apoptosis, and necrosis during the reperfusion phase.
lthough extensive research has been made exploring these molec-
lar pathways, so far, there are no effective neuroprotective drugs
or patients undergoing transient cerebral artery occlusion [3]. Also,
he enthusiasm regarding the use of intraoperative hypothermia as
 neuroprotective adjunct has decreased in latest years, highlight-
ng the need for the development of novel neuroprotective agents
nd strategies [4–6].
Glycogen  synthase kinase-3 (GSK-3), a cytoplasmic ser-
ne/threonine protein kinase, was originally described as a
omponent of the metabolic pathway of glycogen metabolism and
as been involved in a wide range of cellular functions, including
etabolism, cytoskeletal integrity, gene expression, cell division,
nd apoptosis [7]. Several studies have implicated GSK-3 signalling
ransduction pathway in multiple central nervous system diseases,
articularly stroke, traumatic brain injury and neurodegenerative
onditions, such as Alzheimer’s disease, Parkinson’s disease and
myotrophic lateral sclerosis [8,9]. GSK-3, one of the two  isoforms
f GSK-3, is widespread both in developing and adult mammalian
ervous system and its overexpression induces intrinsic apoptotic
ignalling pathway in neuronal cells following hypoxia/ischemia
timulus [10]. The acknowledgement of a potential involvement of
SK-3 in neuronal apoptosis, lead to the development of speciﬁc
ntagonists. Martinez et al. described small heterocyclic thiadia-
olidinones (TDZDs) and their structure–activity relationships as
he ﬁrst non-ATP competitive selective GSK-3 inhibitors [11].
DZDs are small molecules with favourable absorption, distribu-
ion, metabolism, excretion and toxicity properties [12]. TDZD-8 is
 BBB permeable compound and appears to be one the most effec-
ive anti-inﬂammatory and tissue-protective thiadiazolidinones in
onditions, such as stroke, spinal cord injury, kidney injury, arthri-
is, or colitis [12–18]. Furthermore, phase IIb and phase III clinical
rials suggest that TDZDs have a favourable safety proﬁle and may
ecome valuable for the treatment of some neurological diseases
n the near future [19,20].
The  aim of this study was to investigate the effects of a sin-
le dose of TDZD-8 (5 mg/kg) as a possible pre-treatment against
euronal damage in intraoperative transient cerebral artery clip-
ing during intracranial aneurysm surgery. TDZD-8 doses were
etermined in accordance with previous effective studies in central
ervous system and administered with the established therapeutic
ime window in the clinical setting [15,21]. To better reproduce the
urgical procedure, we performed a rodent model of focal cerebral
schemia-reperfusion (I/R).
. Materials and methods
A  total of 28 adult male Wistar rats (240–340 g) housed under
iurnal light conditions with unlimited access to food and water
ere used (n = 14 per group). Animal care followed the recommen-
ations of European Convention for the Protection of Vertebrate
nimals Used for Experimental and Other Scientiﬁc Purposes
Council Directive 2010/63/EU) and National Law 1005/92 (rules
or protection of experimental animals). The Institutional Animal
are and Use Committee approved all animal procedures. All efforts
ere made to minimize animal suffering and to reduce the number
f animals used.
.1.  InterventionAnimals were randomly assigned in two different groups:
DZD-8 (4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione,
igma-Aldrich, St. Louis, MO,  USA) treatment group in which a
ose of 5 mg/kg was administered in the tail vein intravenouslyg Pathology 4 (2014) 361–367
(i.v.)  10 min  previous to ischemia onset or; control group, in which
animals had administered saline i.v. according to protocol. Alloca-
tion concealment was attained by having drug or saline individually
prepared and labelled for each animal according to randomization
by an independent investigator. A single investigator blinded to
treatment carried out the surgical procedures.
2.2. Middle cerebral artery ischemia-reperfusion
Rats were food deprived 12 h prior to surgery. Anaesthesia was
induced by intraperitoneal administration of ketamine (80 mg/kg)
and xylazine (8 mg/kg) mixture, supplemented as needed. Anes-
thetized rats were placed onto a thermostatically controlled
heating pad, a rectal probe was inserted, and body temperature was
monitored and maintained between 36.5 ◦C and 37.5 ◦C. Transient
focal cerebral ischemia was induced by 60-min right MCA  occlu-
sion followed by 24-h reperfusion, as previously reported by our
group [22].
Brieﬂy, under the operating microscope, the right common
carotid artery (CCA), internal carotid artery (ICA) and external
carotid artery (ECA) were exposed and isolated from branches
through a midline neck incision. The ECA was  tied and cut at
approximately 5 mm from the bifurcation and a loose 6-0 silk knot
was placed around the ECA origin. After, microvascular clips were
placed on the CCA and ICA, an ECA stump arteriotomy distal to
the loose knot was performed and a 4-0 nylon silicone rubber-
coated tip monoﬁlament (Doccol Corporation, Sharon, MA,  USA)
was inserted. The suture around the ECA stump and the intralumi-
nal nylon ﬁlament was tightened to prevent bleeding and the clips
were removed. The ﬁlament was gently introduced (19–21 mm)
into the ICA to the level where the MCA  branches out, until laser-
Doppler signal decreased to less than 30% of baseline values,
occluding the right MCA  at its origin at the circle of Willis. After a
60-min period of ischemia, the thread was  cautiously removed re-
establishing the blood ﬂow in the MCA. The ECA was permanently
ligated at the level of bifurcation. Animals were allowed to recover
and euthanized with anaesthetic overdose at 24 h into reperfusion.
2.3. Blood ﬂow measurements
Cortical  cerebral blood ﬂow (CBF) was monitored by laser-
Doppler ﬂowmetry (Periﬂux System 4000, Probe 407, Perimed-
Instruments, Stockholm, Sweden) in the supply territory of the
right MCA  where transient ischemia was to be done, before, dur-
ing occlusion and within 1 h of reperfusion. A small burr hole was
drilled 2 mm  posterior to the bregma and 3.5 mm lateral to the
midline and the micro-Doppler probe positioned above the dura
in a holder glued to the bone. Steady-state baseline values were
recorded before occlusion, and the CBF measured during occlusion
and reperfusion was expressed as a percentage of the baseline val-
ues. Rats with CBF patterns suggesting subarachnoid haemorrhage,
incomplete ischemia (CBF does not decrease to a maximum of 30%
of baseline) or incomplete reperfusion (CBF does not recover to
over 80% of baseline within 30 min  of ﬁlament withdrawal) were
excluded and replaced.
2.4.  Neurological examination
At  24-h, a nine-point scale neurological test (0 = normal to
9 = highest handicap) was performed, as previously described [23].
Four tests were performed by an observer blinded to the treatment
groups in order to assess:
• spontaneous  activity (moving/exploring = 0, moving without
exploration = 1, no displacement = 2);
B.O. Ratilal et al. / Biomedicine & Aging Pathology 4 (2014) 361–367 363
Fig. 1. a–c: bar graphs comparing groups for several endpoints: total infarct volume (a), percentage of hemispheric oedema (b) and NSE plasma levels at 24 h of reperfusion
(c). Infarct volumes are presented as percentages of the contralateral hemisphere (28.02 ± 1.73% in control group compared to 14.70 ± 1.12% in treatment group). Data
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ann–Whitney test.
laterality  in movement (symmetrical = 0, left drifting when ele-
vated  by the tail = 1, spontaneous left drifting = 2, circling to the
left  without displacement or spinning = 3);
resistance  to left forepaw stretching (no stretching allowed = 0,
stretching allowed = 1, no resistance = 2);
parachute reﬂex (symmetrical = 0, asymmetrical = 1, contralat-
eral  forelimb retracted = 2).
Scores obtained for each test were added to obtain the ﬁnal
eurological score.
.5.  Infarct volume and brain oedema assessment
The brains were removed, placed in a brain matrix (World Pre-
ision Instrument, Hertfordshire, UK) and sliced in 2-mm thick
oronal sections, beginning 2 mm from the frontal pole and end-
ng rostral to the cortico-cerebellar junction, resulting in 6 slices
er animal (n = 8 per group). The sections were stained in 2% 2,3,5-
riphenyltetrazolium chloride (TTC) (Sigma-Aldrich, St. Louis, MO,
SA) saline solution for 10 min  at 37 ◦C in the dark and ﬁxed in
% paraformaldehyde at 4 ◦C overnight. Sections were scanned and
nalyzed using ImageJ software version 1.45. Brain infarction was
isualized as areas of unstained (white) tissue, which contrasted
rom brick stained areas of viable tissue. Summing the infarct area
f each coronal slice and multiplying that number by the thick-
ess of the sections allowed the calculation of the total infarct
olume. Right and left hemispheric volumes were calculated sim-
larly. The amount of infarction was expressed in absolute term in the effects of TDZD-8 at 24 h on a 9-point neurologic score. Open circles indicate
iﬁcantly reduced neurologic deﬁcits. Asterisk (*) depicts differences with P < 0.001,
cubic millimetres and as a percentage of the contralateral hemi-
sphere adjusted for brain oedema [24]. An index of brain oedema
was assessed by calculating the percentage increase of size of the
ipsilateral (injured) hemisphere compared with the contralateral
(uninjured) hemisphere. A single observer, blinded to the individ-
ual treatment, performed the described analysis.
2.6. Determination of neuron speciﬁc enolase (NSE) plasma levels
Blood  samples were taken by puncture of the left cardiac ven-
tricle prior to sacriﬁce. Blood was  centrifuged at 10,000 rpm for
10 min  and the isolated serum was  frozen and stored until time
of assay. Serum NSE measurements were performed with an elec-
trochemiluminescence immunoassay, using a sandwich technique
with double monoclonal antibodies directed against NSE (Roche
Diagnostics, Mannheim, Germany) and an Elecsys 2010 analyser
(Roche Diagnostics, Mannheim, Germany). Data were normalized
to nanograms per millilitre of plasma.
2.7. Histology and immunohistochemistry procedures
Rat brains were removed, ﬁxed in 4% paraformaldehyde
in  PBS for 72 h at room temperature, dehydrated through a
graded ethanol series and embedded in parafﬁn (n = 3 per group).
Hematoxilin–Eosin (H–E) staining was performed as previously
described [25]. Images were acquired using a bright ﬁeld Axioscop
microscope (Zeiss, Göttingen, Germany).
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For Fluoro-Jade staining, 6 m thick coronal sections were
eparafﬁnised and rehydrated. Slides were ﬁrst immersed in 100%
lcohol for 3 min  followed by 1 min  in 70% alcohol and 1 min  in
istilled water. The slides were then transferred to a solution of
.06% potassium permanganate for 15 min  on a shaker table and
rotected from light. The slides were after rinsed in distilled water
or 1 min  and immersed in Fluoro-Jade B (Chemicon, Temecula,
A, USA) staining solution 0.001% for 30 min  with moderate agi-
ation. Slides were rinsed for one min  in each of three distilled
ater washes and dried at room temperature. The dry slides were
leared by immersion in xylene for at least a minute before cover
lipping with DPX (Sigma-Aldrich, St. Louis, MO,  USA). The tissue
as then examined using an epiﬂuorescent AxioScope microscope
Zeiss, Göttingen, Germany) with blue (450–490 nm)  excitation
ight. The number of positive Fluoro-Jade B neurons were counted in
 sections of 0.16 m2 (n = 3 per group) within the region of inter-
st using ImageJ software version 1.45 and expressed as positive
ells/section.
For immunostaining, 6 m thick coronal sections were submit-
ed to antigen retrieval in 20 mM citrate buffer with 1.5% H2O2
or 15 min  at room temperature in the dark, incubated for 10 min
n Tris–EDTA buffer at 84 ◦C and blocked for 1 h at room temper-
ture in 1% bovine serum albumin (BSA) in phosphate buffered
aline (PBS). Primary antibody, rabbit anti-p-Akt (1:100, CellSig-
aling Technology, Beverly, MA,  USA) was used in 0.5% BSA in PBS
vernight at 4 ◦C. After washing in PBS, sections were incubatedon with delineated infarct area of control and TDZD-8-treated rats, H–E  staining; b:
 spongiosis (arrows) and perivascular oedema ( ) in control animals or its absence
for  1 h at room temperature with antibodies anti-rabbit coupled
to AlexaFluor 568 (#A11077, 1:1000, Invitrogen, Carlsbad, CA,
USA) in 0.5% BSA in PBS, incubated for 20 min  in 4,6-diamidino-2-
phenylindole (DAPI) and mounted with Shandon Immu-MountTM
Aqueous Non-ﬂuorescing Mounting Medium (Thermo Scientiﬁc,
Rockford, IL, USA). Tissue sections were visualized with a epiﬂuo-
rescent AxioScope microscope (Zeiss, Göttingen, Germany) and the
number of total nuclei (DAPI staining) and the ones positive for p-
Akt counted to present the results as percentage of p-Akt-positive
nuclei (2 sections within the region of interest, n = 3 per group).
2.8. Western blot analysis
For  western blot analysis (n = 3 per group), frozen tissue sam-
ples cells were lysed in RIPA buffer containing Tris 50 mM (pH 8.0),
5 mM EDTA (pH 8.0), 150 mM NaCl, 1% NP-40, 10% glycerol and
0.1% SDS, and sonicated for 20 s. The lysate was centrifuged at
14,000 g for 10 min  at 4 ◦C and the supernatants were collected
and stored at –80 ◦C. Protein concentrations were determined
using Nanodrop ND-1000. Cell extracts containing equal amounts
of protein (100–150 g) were separated on sodium dodecyl
sulphate–polyacrylamide gel electrophoresis and transferred to a
nitrocellulose membrane. The membranes were blocked with 5%
non-fat milk, incubated with the primary antibody overnight at
4 ◦C anti-rabbit p-Akt (1:1000) (#12178, Cell Signaling, Danvers,
MA, USA), anti-rabbit Akt (1:1000) (#4691, Cell Signaling, Danvers,
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A,  USA), and then with a horseradish peroxidase-labelled sec-
ndary antibody for 1 h at room temperature. After extensive
ashes, immunoreactive bands were detected by LumiGLO® (Cell
ignaling, Danvers, MA,  USA) and visualized by autoradiography
ith Hyperﬁlm ECL. Phosphorylation levels of Akt were analysed by
he ratio of p-Akt to total Akt levels and expressed as fold compared
o contralateral MCA  occlusion hemisphere.
.9. Statistical analysis
Statistical  analysis was performed using GraphPad Prism soft-
are version 6.0. Parametric data were analysed using Student’s
-test for single comparisons between groups and non-parametric
ata (neurologic scores) were subjected to the two-tailed
ann–Whitney test. Data are presented as means ± SEM (standard
rror of the mean) for n observations, where n represents the num-
er of animals studied. For histological scoring and western blot
nalysis, each data point represents analyses of brain sections taken
rom 3 individual rats. A P value of less than or equal to 0.05 was
he threshold considered for a statistically signiﬁcant difference or
ssociation.
. Results
All animals lost between 10 to 18% of body weight during the 24-
 recovery period with no signiﬁcant differences between groups.
ormothermia was maintained in all animals. There were no signif-
cant differences between groups with respect to CBF pattern and
lycaemia values during the procedure.
Prophylactic administration of TDZD-8 resulted in signiﬁcant
ifferences between groups for most outcomes and endpoints eval-
ated (Fig. 1). The whole brain infarct volume was signiﬁcantly
ifferent between groups (265.46 ± 13.88 mm3 for control group
nd 125.99 ± 11.26 mm3 for treatment group, n = 8 per group) and. a: representative images of brain section stained for degenerating neurons using
o-Jade staining neurons per 0.16 m2 in 4 sections for each rat of the infarcted area.
 differences with P < 0.001.
treatment  group had a signiﬁcant decrease in the ipsilateral hemi-
spheric oedema (9.74 ± 1.39% compared to 3.99 ± 0.56%, n = 8 per
group). TDZD-8 administration also prevented the rise of NSE
plasma levels (0.20 ± 0.06 ng/mL in treatment group, compared
to 1.88 ± 0.07 ng/mL in control group, n = 13 for treatment group
and n = 8 for control group). Consistently, rats treated with TDZD-
8 presented signiﬁcantly less neurological deﬁcits compared to
the control group (n = 14 per group). Neuropathological examina-
tion corroborated these ﬁndings: H–E staining performed in the
ischemic area showed less neuropil spongiosis and less perivas-
cular oedema on TDZD-8-treated group (Fig. 2) and there was  a
50% reduction in the number of degenerating Fluoro-Jade positive
neurons in TDZD-8 treatment group (421.3 ± 45.61 compared to
210.8 ± 16.14 positive cells per section) (Fig. 3). Western blot anal-
ysis revealed that p-Akt and total Akt expression levels exhibited
no signiﬁcant changes between groups (data not shown); instead
immunostaining techniques revealed that TDZD-8 signiﬁcantly
increased p-Akt nucleus translocation (22.7 ± 3.44% of positive p-
Akt nuclei in control group compared to 34.3 ± 3.61% in treatment
group) (Figs. 4 and 5).
4.  Discussion
To our knowledge, this study provides ﬁrst evidence that a sin-
gle TDZD-8 pre-treatment dose protects rat brain against injury
following 60-min transient MCA  ischemia. Our data demonstrates
that for cerebral I/R injury, TDZD-8:
• reduced brain damage extent – 48% reduction on the infarct vol-
ume  and 59% reduction of the hemispheric oedema;
• diminished the number of apoptotic/degenerating neurons;
• improved neurological performance at 24 h;
• prevented  plasma rise of NSE.
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NSE is rapidly released by injured neurons, reaching its maxi-
um at 24 h, and is assumed to be a reliable marker to follow-up
euronal damage since the plasma levels of NSE correlate with the
xtent of cerebral infarction [26].
Blood glucose levels during ischemia or reperfusion were not
ifferent between groups, indicating that the effects induced by
DZD-8 are independent from this variable.
GSK-3 inhibition has been shown to induce neuroprotective
ffects in cerebral ischemia by suppressing neuronal apoptosis and
rotecting against the loss of barrier integrity due to a decrease
n the generation of several pro-inﬂammatory mediators and pre-
enting leukocyte adhesion and migration into the brain [14,27].
urthermore, GSK-3 inhibition is thought to promote autophagy
ig. 5. Bar graph representing the percentage of positive p-Akt nuclei in the infarct
rea, comparing ipsilateral to contralateral hemispheres. Data are means ± SEM (2
ections for each individual, n = 3 per group). Asterisk (*) depicts differences with
 < 0.05.s of the infarcted area of the I/R injured and contralateral hemispheres after double
 are also presented. Scale bar equals 50 m.
activation in ischemic injury, an intracellular catabolic process
by which cells remove their damaged organelles for the mainte-
nance of cellular homeostasis, and to induce astrocyte sensitization
and tolerance to inﬂammatory molecules [28,29]. These neuronal
pro-survival effects are consistent with the fewer positive degener-
ating/necrotic neurons stained with Fluoro-Jade and lower plasma
levels of NSE seen in the treatment group. GSK-3 inhibition has
been proposed to be a potent and effective therapeutic approach for
attenuating inﬂammatory response associated to brain microvas-
cular endothelial cells dysfunction, which includes preservation of
BBB tightness by promoting tight junction protein stability [27,30].
It is possible that TDZD-8 attenuates BBB disruption and conse-
quential secondary brain injury.
The Akt/GSK-3 pathway is a central mediator in signal trans-
duction pathways that help to regulate cell growth, metabolism,
inﬂammation and cell survival. Following cerebral ischemia, acti-
vated phosphorylated-Akt (p-Akt) levels transiently increase in
neurons, and this elevation is believed to be a neuroprotective
response [31]. Activated protein kinase p-Akt phosphorylates a
number of downstream cytosolic and nuclear proteins that reg-
ulate mitochondrial activity, cell growth, and cell survival. The
cytosolic modulation includes the inhibition of Bcl-2-associated
death promoter (BAD) protein, caspases and GSK-3 itself [31].
Phosphorylated-Akt has been shown to translocate to the nucleus
where it phosphorylates several other targets, such as p53 tumour
suppressor, Forkhead box transcription factors, nuclear S6-kinase-
related kinase (SRK), and Nur77, therefore inhibiting their activity
and ability to induce the expression of death genes [32,33]. We
found that TDZD-8 did not affect total p-Akt expression in our I/R
experiment, which is explained by the fact that GSK-3 inhibi-
tion occurs downstream to the phosphorylation site of Akt and
its potential targets. Interestingly, an increased translocation of
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-Akt into the nucleus was observed following TDZD-8 treatment,
uggesting Akt signalling pathway activation. Accordingly, phos-
horylation of Akt appears to be essential for its intranuclear
ermanence and recent evidence indicates that Akt plays its roles
y regulating its phosphorylation state, rather than its protein
xpression [32,34,35].
We  recognize some caveats in our study. The mechanism of
ction by which TDZD-8 acts in focal cerebral I/R is lacking and
equires further investigation. Also, it would be interesting to per-
orm dose-response and time course experiments. This dynamics
ould be of both experimental and clinical relevance.
. Conclusions
The efﬁcacy of intraoperative drugs most commonly used during
neurismal clipping surgery offer limited neuroprotection. It has
een recently described that thiadiazolidinones compounds have
otent anti-inﬂammatory and tissue-protective effects. Our study
eveals that it is likely that the neuroprotective effects induced
y TDZD-8 are due to a complex and mixed synergic interaction
etween GSK-3 inhibition and Akt modulation. In conclusion,
DZD-8 is neuroprotective in vivo and may  have a role in the clini-
al setting as a pre-treatment against neuronal damage induced by
ransient cerebral artery occlusion during cerebrovascular proce-
ures.
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